Waldenström Macroglobulinemia: Clinical and Immunological Aspects, Natural History, Cell of Origin, and Emerging Mouse Models

Siegfried Janz

Department of Pathology, University of Iowa Carver College of Medicine, 1030 ML, Iowa City, IA 52242, USA

Correspondence should be addressed to Siegfried Janz; siegfried-janz@uiowa.edu

Received 2 July 2013; Accepted 26 July 2013

Copyright © 2013 Siegfried Janz. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Waldenström macroglobulinemia (WM) is a rare and currently incurable neoplasm of IgM-expressing B-lymphocytes that is characterized by the occurrence of a monoclonal IgM (mIgM) paraprotein in blood serum and the infiltration of the hematopoietic bone marrow with malignant lymphoplasmacytic cells. The symptoms of patients with WM can be attributed to the extent and tissue sites of tumor cell infiltration and the magnitude and immunological specificity of the paraprotein. WM presents fascinating clues on neoplastic B-cell development, including the recent discovery of a specific gain-of-function mutation in the MYD88 adapter protein. This not only provides an intriguing link to new findings that natural effector IgM⁺IgD⁺memory B-cells are dependent on MYD88 signaling, but also supports the hypothesis that WM derives from primitive, innate-like B-cells, such as marginal zone and B1 B-cells. Following a brief review of the clinical aspects and natural history of WM, this review discusses the thorny issue of WM’s cell of origin in greater depth. Also included are emerging, genetically engineered mouse models of human WM that may enhance our understanding of the biologic and genetic underpinnings of the disease and facilitate the design and testing of new approaches to treat and prevent WM more effectively.

1. Clinical Aspects of WM: A Brief Overview

1.1. Definition and Classification. The 2008 World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues [1] defines Waldenström macroglobulinemia (WM) as a type of lymphoplasmacytic lymphoma (LPL) as a type of lymphoplasmacytic lymphoma (LPL) that involves the bone marrow and is associated with a monoclonal immunoglobulin (Ig) of the M class in the serum. The monoclonal IgM is usually referred to as IgM paraprotein or “M spike”—or mIgM for short. LPL is a low-grade malignancy of the mature B-lymphocyte lineage that exhibits a cytological spectrum of lymphoplasmacytic differentiation that ranges from small B cells to fully differentiated plasma cells (PCs). Between these extremes lies a sizable, if not predominant, fraction of cells with intermediate features and, therefore, designated lymphoplasmacytoid or lymphoplasmacytic cells (LPCs) [2]. Sometimes these cells are referred to as plasmacytoid or plasmacytic lymphocytes. Although LPL is characteristically associated with an mIgM that can be readily detected by serum protein electrophoresis, LPL does not always lead to WM. This is because approximately 5% of LPLs either produce a paraprotein that is not of the M class (but instead belongs in most cases to the A class or one of the four G subclasses) or do not produce paraprotein at all (nonsecretory variant). Similarly, LPL is not the sole underlying cause of a serum IgM spike, because paraproteins of this sort can also be produced by other types of B cell lymphoma with plasmacytic differentiation potential (e.g., marginal zone B cell lymphoma, MZL) [3] or, in rare cases, by bona fide plasma cell neoplasms, such as IgM⁺ plasmacytoma or multiple myeloma (MM) [4]. In sum, even though LPL does not always lead to WM and the occurrence of a serum IgM spike is not pathognomonic for this disease, WM is always caused by IgM⁺ LPL.

1.2. Symptoms Attributable to Tumor Growth. The great majority of patients with LPL exhibit distinctive clinical features that can be attributed either to tissue infiltration
with malignant B cells or IgM-dependent changes in serum (hyperviscosity syndrome) and/or various tissue sites (immunoglobulin deposition disease, autoimmune). With regard to tissue infiltration by tumor cells, the replacement of the normal hematopoietic bone marrow with WM cells usually leads to a progressive normochronic or normocytic anemia and, to a lesser extent, suppression of other blood cell lineages leading, for example, to thrombocytopenia. Tumor infiltrates in solid tissues may clinically present as organomegaly, including hepato- and splenomegaly as well as lymphadenopathy. In rare cases, malignant infiltration of the lung (accompanied by pleural effusion) [5], the gastrointestinal lymphadenopathy. In rare cases, malignant infiltration of cell lineages leading, for example, to thrombocytopenia. Anemia and, to a lesser extent, suppression of other blood usually leads to a progressive normochromic or normocytic of the normal hematopoietic bone marrow with WM cells regard to tissue infiltration by tumor cells, the replacement serum (hyperviscosity syndrome) and/or various tissue sites with malignant B cells or IgM-dependent changes in

1.3. Symptoms Attributable to mlgM. Under normal conditions, IgM predominantly occurs in serum in pentameric form. Five IgM monomers, each consisting of two \( \mu \) heavy chains and two \( \kappa \) or \( \lambda \) light chains, are covalently linked by the J or joining chain, resulting in a supramolecular complex that is often schematically depicted as a snow flake or five-leaved shamrock. The pentameric structure of IgM results in a large molecular mass (∼970 kilodalton), high avidity to antigen (10 antigen-binding sites), and high potential for complement activation, but the flip side of these features is poor diffusion properties, low concentration in interstitial fluids, and poor ability to leave the blood stream. In patients with WM, the elevated concentration of monoclonal IgM can lead to serum hyperviscosity, a key distinguishing feature of the disease. Symptoms include bleeding and a multitude of ocular, neurologic, and cardiovascular manifestations [9]. Thanks to an earlier recognition of the disease in recent years, serum hyperviscosity is only observed in a minority of patients at diagnosis [10, 11]. As a rule, symptoms of hyperviscosity are rare in patients with IgM levels below 30–40 g/L and serum viscosity values below 4 cP (centipoise). This threshold corresponds to a 2.5-fold increase relative to normal serum viscosity, which is in the neighborhood of 1.6 cP. Some symptoms of WM are attributable to tissue deposition of IgM, not to increased serum viscosity. IgM deposits may occur in kidney (glomeruli), intestine, and skin, leading to proteinuria, diarrhea, and characteristic papules (IgM storage papules or cutaneous macroglobulinosis) [12, 13], respectively. Kidney involvement usually leads to slowly progressive loss of function rather than acute renal failure [14, 15]. Primary amyloidosis due to monoclonal light chain deposition has been found, in descending order of frequency, in the heart, peripheral nerves, kidneys, soft tissues, liver, and lungs [16]. In contrast, secondary (reactive) amyloidosis is rarely seen [17]. WM patients may also exhibit symptoms that are attributed to autoantibody activity of IgM. IgMc with specificity to certain red blood cell antigens may lead to chronic immune hemolytic anemia that is associated with elevated cold agglutinin titers [18, 19]. The combination of mlgM, urticaria, fever, and arthralgia is known as Schnitzler syndrome [20]. Neuprophathies, which are caused in part by immunoreactivity of IgM to myelin-associated glycoprotein (MAG) [21], IgM-mediated glomerulonephritis, angioedema, and acquired von Willebrand disease have all been reported. A laboratory finding without adverse health effects in approximately one fifth of patients with WM is the propensity of IgM to undergo precipitation at temperatures below normal body temperature; for example, during storage of serum at 4°C in a refrigerator. However, in a small subset of cases (<5%), this phenomenon, known as cryoglobulinemia, causes symptoms including Raynaud syndrome, joint pain, and purpura and other skin changes [22].

1.4. Differential Diagnosis. As stated in the introductory section entitled “definition and classification,” neither the presence of a malignant LPC clone in bone marrow nor the detection of an IgM spike in serum is pathognomonic for WM. Instead, these changes may also be caused by other IgM+ malignancies of the mature B cell lineage related to but distinct from WM. Splenic marginal zone lymphoma (SMZL) appears to be a particular concern and sometimes a challenge for clinicians, yet mantle cell lymphoma (MCL), rare cases of IgM-producing multiple myeloma (IgM-MM), and B cell chronic lymphocytic leukemia (B-CLL) must also be considered when a patient presents with symptoms suggestive of WM. SMZL can be distinguished from WM on the basis of immunophenotypic and molecular cytogenetic findings: CD11c (integrin alpha X chain) is more highly expressed in patients with SMZL, whereas CD25 (IL-2 receptor alpha chain) is twice as common in WM [23]. CD10, a member of the integrin adhesion surface receptor family of protein, is invariably absent on WM cells but detected in 40% of patients with SMZL [23]. The genomic abnormality most common in SMZL, loss of 7q31-32 [24], is not seen in WM. Additionally, SMZL exhibits a specific gene expression signature upon microarray-based, genome-wide analysis of the tumor transcriptome [25, 26]. MCL can be distinguished from WM based on clinicohistopathologic findings [27] and, in terms of cancer cytogenetics, the almost invariable occurrence of the hallmark t(11:14)(q13;q32) translocation that recombines \( IGH \) (Ig heavy-chain locus) on chromosome 14 and \( CCND1 \) (cyclin D1) on chromosome 11 [28, 29]. IgM+ myeloma can be
distinguished from WM by virtue of its pronounced plasma cell morphology and presence of lytic bone lesions. Renal insufficiency is more common in IgM-MM than in WM. Chromosomal translocations involving IgH, particularly the cyclin D1-activating (11;14)(q13;q32) exchange mentioned previously, occur in IgM-MM but not WM [30, 31]. B-CLL may mimic WM clinically, but the morphological and immunophenotypic features of the tumor cells are usually sufficiently different from WM to avoid confusion. CLL is positive for CD5 (surface protein that mitigates activating signals from the B cell receptor) and CD23 (low-affinity IgE receptor) by flow cytometry. Another area of concern from a diagnostic and clinical management point of view is the possibility that the low-grade lymphoma, WM, progresses to the high-grade lymphoma, diffuse large B cell lymphoma (DLBCL). This is usually associated with aggressive clinical course, profound cytopenias, extramedullary disease, and poor outcome [32]. The potentially diverse nature of “histological transformation events” in patients with WM, including those involving EBV (Epstein-Barr virus) infection, is increasingly recognized [32].

1.5. Risk Stratification and Prognosis. Owing to novel agents and combination therapies briefly discussed in the following section, overall survival of WM patients of all ages has improved [33–35]. Nonetheless, WM remains an incurable disease that exhibits significant variations in clinical course and outcome [36]. The latter may depend in part on differences between patient cohorts in different studies (e.g., tumor burden at presentation) but may also be a consequence of differences among individual tumors with respect to genetic, epigenetic, and biological determinants of tumor growth and IgM production [37–40]. The recently updated International Prognostic Scoring System for WM [41] uses five determinants for disease staging: age (above 65 is a negative risk factor), hemoglobin (≤115 g/L), platelets (≤10^5 per microliter), β2 microglobulin (>3 mg/L), and mIgM (>70 g/L). After assessing one point for each negative risk factor, the patient can be categorized as low risk (≤1 except age), intermediate risk (2 or older than 65 yrs) or high risk (>2). The 3 risk groups are associated with a median survival of more than 10 years (143 months), 8 years (99 months), and 3.5 years (44 months), respectively. Age has a profound impact on risk stratification and prognosis as, by definition, patients older than 65 years cannot be assigned to the low-risk category regardless how subdued the disease might be. In comparison to age, IgM levels are weighed more forgivingly, as this parameter does not enter the staging system until a threshold of 70 g/L is exceeded. This is perhaps somewhat of a surprise given that mIgM levels correlate with abundance of monotypic plasma cells in bone marrow [42], a finding that many may have intuitively considered a marker of disease progression. Ongoing efforts to refine the staging system focus on serum levels of lactate dehydrogenase, which have been recently shown to stratify high-risk patients into two subgroups with significantly different outcomes [43, 44], and the immunoglobulin free light-chain assay, which is under review as a potential prognosticator of patients with WM [45]. Importantly, the prognostic scoring system for WM should not be used for treatment decisions. This is the prerogative of clinicians, who will base the determination whether a patient requires treatment or not on the available clinical and laboratory findings, as well as the preferences of the patient with WM. With regard to overall outcome of WM, it is important to realize that WM takes an indolent course and patients with WM usually are of an advanced age. In fact, nearly half of them succumb to diseases of the elderly population—unrelated to WM [11]. This led to the introduction of cause-specific survival as an important outcome measure for patients with WM, which censors (disregards) patients who die of causes other than WM [46].

1.6. Treatment. Treatment is reserved for symptomatic patients. It usually consists of alkylating agents (chlorambucil, cyclophosphamide, and melphalan), nucleoside analogues (cladribine and fludarabine), proteasome inhibitors (bortezomib), dexamethasone, and monoclonal antibody to CD20 (rituximab). Regimens for frontline and salvage treatments, using the after mentioned drugs either alone (monotherapy) or in combination, have been established and expertly reviewed by leading WM clinicians [11, 47–50]. Therapeutic options involving drugs can be supplemented with hematopoietic stem cell (HSC) transplantation, particularly with the autologous version, which appears to be highly effective but underutilized [51].

A recently completed phase 3 trial in patients with WM, which is thought to have defined a new benchmark for future clinical studies on the disease, demonstrated that fludarabine monotherapy was more effective than chlorambucil in terms of progression-free survival (37.8 versus 27.1 months), duration of response (38.5 versus 21.3 months), and overall survival (median not reached versus 69.8 months). The results suggested that fludarabine may be the drug of choice for frontline treatment of patients that are not candidates for autologous HSC transplants but have poor prognostic factors and/or are in need of rapid disease control [52]. Although the clinical trial (an area of research that is notorious for lack of well-designed phase 3 trials) reported interesting findings and was well received, it may not lend itself to defining a new standard of care because of inadvertent shortcomings [53]. For example, the trial’s treatment plan did not incorporate rituximab, even though this therapeutic antibody has become a mainstay in the care for patients with WM [54–56].

Additional drugs that may be useful for patients with WM include monoclonal antibody to CD52 (alemtuzumab) [57], immunomodulatory agents (thalidomide [58] and lenalidomide [59]), and molecularly targeted small-molecule inhibitors of cellular signal transduction pathways, such as the mTOR (mammalian target of rapamycin) inhibitor, everolimus [60], the AKT (v-akt murine thymoma viral oncogene homolog 1) inhibitor, perifosine [61], and newly emerging HDAC (histone deacetylase) inhibitors [62]. A simple and almost forgotten drug, the nitrogen mustard-related alkylating agent bendamustine—which had been developed as early as 1963 in the former East Germany, where it remained dormant and unavailable to the Western
1.7. Key Points and Future Directions. A synopsis of salient points covered in this chapter is schematically presented in Figure 1. WM is a low-grade blood cancer of the mature B-lymphocyte lineage that is closely related to, but distinct from, other types of low-grade B cell lymphoma, such as SMZL, MCL, and B-CLL. The features of WM and its differential diagnosis are well established. Treatment of WM is highly effective, and long-term control with good clinical management is possible. Nevertheless, WM remains an incurable neoplasm at this juncture. Experienced WM clinicians increasingly emphasize that the long survival and advanced age of the great majority of patients with WM call for greater awareness and consideration of quality-of-life and treatment-associated morbidity issues. Selecting the most appropriate interventions for patients with WM and managing the complications of progressive disease remain ongoing tasks. Expert reviews providing tons of valuable information about clinical aspects of WM are available [48, 50, 68, 69].

2. Epidemiology and Natural History of WM

2.1. Incidence. With an annual overall incidence rate of approximately 3 cases per one million persons, WM accounts for a little less than 2% of non-Hodgkin lymphomas in the United States. This number corresponds to approximately 1,500 new cases per year in the US [70]. Incidence in men and Caucasians is higher than in woman and African Americans, respectively [71, 72]. The median age at diagnosis is approximately 70 years [73]. The strongest risk factor for WM is IgM MGUS, the "premalignant" precursor condition of WM. On average, IgM MGUS progresses to frank WM (or one of its relatives among the B cell proliferative disorders) at an annual rate of 1.5% [74, 75]. This means that in a hypothetical cohort of 150 individuals with IgM MGUS (the assembly of which is not an easy task to begin with) only one individual per annum will go on to develop WM. Obviously, the slow progression rate causes great difficulties for designing sufficiently powered intervention trials; for example, those aimed at evaluating whether chemoprevention can block the IgM MGUS to WM transition. Trials along this line may take decades to produce meaningful statistical results. This backdrop provides a strong rationale for developing experimental model systems of WM, with which novel tumor prevention approaches can be evaluated in a reasonable time frame and at reasonable costs. Model systems of this sort may take advantage of nonmammalian organisms, such as round worm (Caenorhabditis elegans), fruit fly (Drosophila melanogaster), zebra fish (Danio rerio), or frog (Xenopus laevis, tropicalis), or of mammals, such as rat, rabbit, dog, pig, and others. Model organisms of human cancer are widely available in research laboratories around the world and have been used extensively to shed light on mechanisms of tumor development and progression. Chapter 6 of this spotlight paper will argue that accurate, genetically engineered mouse models of human WM may be particularly useful for designing and testing new prevention approaches to WM.
of the disease. The studies involved hundreds of thousands of individuals and arrived at the same conclusion despite different study designs. Two studies relied on surveys and were performed in the US. Two studies were population based and carried out in Sweden. The following observations were made. Two nationwide surveys of US veterans explored the role of antigen stimulation in the pathogenesis of WM. The first survey, which included 146,394 individuals infected with hepatitis C virus (HCV) and 572,293 controls, revealed that HCV infection increased the risk of developing WM approximately 3-fold [76]. The second survey, which identified 361 patients with WM among 4 million U.S. veterans followed for up to 27 years, found a ~2.5-fold elevated risk of WM in individuals with a personal history of an autoimmune disease and a smaller but still notably elevated risk conferred by hepatitis, rickettsiosis, and infection with human immunodeficiency virus (HIV) [77]. The Swedish studies produced similar results. The first one evaluated 2,470 patients with LPL/WM and 9,698 matched controls, as well as almost 30,000 first-degree relatives of the patients and controls. It uncovered an association of LPL/WM with a personal history of autoimmune diseases (e.g., Sjögren syndrome, hemolytic anemia, polymyalgia rheumatica, and giant cell arteritis) and infectious diseases (e.g., pneumonia, pyelonephritis, sinusitis, herpes zoster, and influenza). Additionally, it revealed a link of LPL/WM with a family history of Sjögren syndrome, autoimmune hemolytic anemia, Guillain-Barre syndrome, cytomegalovirus, gingivitis/periodontitis, and chronic prostatitis [78]. The second study assessed 5,403 patients with MGUS and 21,209 matched controls, together with their respective first-degree relatives. It showed that personal and family history of autoimmune disease were independently associated with increased risk of MGUS. It also linked a personal history of infection and chronic inflammation (but not a family history) to increased risk of MGUS [79]. These findings furthered our understanding of the underlying cause of WM by implicating sustained B cell stimulation with self and/or exogenous antigen in the pathophysiology of the disease.

2.3. Genetic Predisposition. Familial clustering of LPL/WM, which has been documented repeatedly in independent studies going back to the 1980s [80–83], points to inherited traits or “WM alleles” that predispose affected individuals to IgM MGUS and WM. The findings indicated that WM alleles segregate in extended families that exhibit genetic proclivity to WM. This concept was recently extended by a large study that involved 1,539 patients with WM and 605 patients with LPL. It showed that first-degree relatives of patients with LPL/WM had a significantly increased risk of developing (1) WM themselves, (2) MGUS (including IgG and IgA), or (3) a type of NHL that is related to WM in terms of biology and clinical presentation (e.g., B-CLL) [84]. The result supports the existence of common B-lineage cancer susceptibility alleles that render carriers susceptible to both LPL/WM and a number of “kindred” lymphoproliferative disorders [85, 86]. A dominant or codominant genetic trait appears to be more likely for these alleles than a recessive trait [87]. An important but difficult task is the identification of common lymphoma and WM alleles. Projects of this nature often begin with microarray-based genome-wide linkage analysis a.k.a. GWAS (genome-wide association studies) of affected individuals. The first analysis was successfully completed by Mary McMaster and her associates. They investigated 11 families at high risk for WM. Included were 122 individuals, of which 34 and 10 had developed frank WM and IgM MGUS, respectively. The strongest evidence of linkage was found on chromosomes 1q and 4q, but additional WM loci are suspected on chromosomes 3 and 6 [88]. This approach may also be helpful to identify genetic markers that predict progression from IgM MGUS to frank WM [89], a critical knowledge gap. Another priority for future research is the elucidation of gene and environment interactions; that is, how do genetic polymorphisms in the germ line (WM alleles) cooperate with environmental factors (e.g., infectious agents) to drive WM? Well designed and sufficiently powered population-based studies [90] may be key for further progress on the elucidation of genetic networks that predispose to WM.

2.4. Tumor Genetics and Microenvironment. From a biochemical perspective, WM cells exhibit heightened and/or constitutive activation of cellular signal transduction pathways that have been implicated not only in the growth, proliferation, and survival of malignant B cells, but also in the acquisition of resistance to therapeutic agents in patients with WM. Signaling pathways of this sort include PI3K-AKT-mTOR [91], NFκB [92, 93], Src tyrosine kinases [94], BCL6-BLIMP1-XBPI [95], and SDF-1/CXCR4/VLA-4 [96]. The biological factors that drive elevated signaling activity in WM are poorly understood, but some of the genetic factors have been revealed in genomic studies of WM. These include PRDM1, which encodes the master regulator of B cell and plasma cell differentiation, BLIMP1; TNFAP13 (tumor necrosis factor, alpha-induced protein 3), which is better known as A20; and, rarely, TRAF3, which encodes the adapter protein, TNF receptor-associated factor 3 [97]. Exciting new lines of investigation concern the deregulated expression of micro-RNAs (miR) in WM cells, with miR-155 receiving the greatest attention at this time [98], and the highly recurrent mutation in the MYD88 adapter protein that replaces a leucine (L) residue at position 265 with a proline (P) [99]. The significance of MYD88L265P will be discussed in greater depth in Section 5.

Widely recognized in the WM community is the crucial role the bone marrow microenvironment plays in tumor development and maintenance [100]. Bone marrow from WM patients contains elevated numbers of mast cells [101], which use CD70 (a ligand for the TNF-receptor superfamily member, CD27) on the cell surface to bind soluble CD27 (sCD27) secreted by tumor cells [102]. The CD27-CD70 interaction activates mast cells to produce TNF family proteins, such as CD40L, APRIL, and BLYS, which, in turn, stimulate WM cells to release more CD27, thereby establishing a classic feed-forward cytokine activation loop between mast cells and tumor cells. There is widespread agreement on
the importance of the proinflammatory cytokine, IL-6, for WM. IL-6 is mainly produced by bone marrow stromal cells (BMSCs) in a paracrine fashion. It binds to the IL-6 receptor (composed of gp80 and gp130) on tumor cells where it activates Jak-Stat3 signaling. This leads to secretion of CCL5 (chemokine C-C motif ligand 5 a.k.a. RANTES), which binds to CCR3 (C-C chemokine receptor type 3 or CD193, a member of family 1 of the G protein-coupled receptors) on BMSCs where it stimulates more IL-6 production. The IL-6/CCL5 axis is thus another feed-forward cytokine loop between tumor and bystander cells in WM. IL-6 is not only upregulated in tumor cells [103] but—together with its target, C-reactive protein (CRP)—present at elevated levels in the sera of WM patients [104, 105]. WM cells also interact with bone marrow endothelial cells (BMECs) by virtue of Ephrin-B2/Eph-B2 signaling [100], a pathway for increased adhesion of tumor cells to endothelial cells and, perhaps, for cell adhesion-mediated drug resistance in patients undergoing chemotherapy. Homing of WM cells to the bone marrow is regulated, in part, by the BMSC-secreted chemokine SDF-1 (stromal cell-derived factor 1 that is officially designated regulated, in part, by the BMSC-secreted chemokine SDF-1 alpha [stromal cell-derived factor 1 alpha]), which binds to the CXCR4 receptor (CD184, fusin) on the tumor cells. Last but not least, WM cells also interact with bone marrow extracellular matrix components, triggering signaling pathways in tumor cells that are less well known but deserving of additional study [100].

2.5. Key Points and Future Directions. A simplified scheme on the pathophysiology of WM is depicted in Figure 2. Despite encouraging progress in the past decade, our knowledge of the natural history of IgM+ LPL remains superficial. This is particularly true of the etiology of and genetic predisposition to WM, as well as the sequence of genetic and epigenetic changes that underlie malignant transformation of WM cells. Thanks to the availability of a sophisticated armamentarium of molecular cytogenetic methods (e.g., fluorescence in situ hybridization [FISH] and spectral karyotyping [SKY]) and high-throughput genomic methods—such as array-based global gene expression profiling, single-nucleotide polymorphism (SNP) analysis, comparative genomic hybridization on microarrays (aCGH) and, more recently, whole-exome and whole-genome sequencing—we have an increasingly detailed understanding of the WM oncogene. Our appreciation of the tumor microenvironment has also increased, although many pieces of that puzzle are still missing. Excellent minireviews on the subject matter covered in this chapter are available in a 2013 proceedings issue of Clinical Lymphoma, Myeloma & Leukemia published on the occasion of the 7th International Workshop on WM held in Newport, Rhode Island [106].

3. Immunophenotype and Immunological Specificity

3.1. Immunophenotype. WM cells exhibit an immunophenotype that is consistent with a mature IgM⁺ B cell that is poised to enter into the pathway of plasmacytic differentiation, but for reasons that are not obvious, is unable to complete it. The κ to λ light-chain usage of the hallmark mIgM protein is skewed in favor of the former, with a ratio of 5 to 1. In serum of healthy adults, this ratio is 2 to 1. The reason for the biased utilization of κ light chains is not known.

The lymphocytoid portion of the tumor cell clone typically expresses surface IgM in conjunction with pan B cell markers, including CD19 (a B cell receptor [BCR] coreceptor that decreases the threshold for antigen-dependent stimulation of BCR signaling), CD20 (a phosphoprotein that optimizes humoral immune responses to T-independent [TI] antigens), CD22 (a sialic acid-binding, immunoregulatory transmembrane lectin that prevents overactivation of the immune system and development of autoimmunity), and CD79a (an accessory component of the BCR known as lgs). Nuclear immunoreactivity of lymphocytoid cells includes BCL2 (B cell CLL/lymphoma 2, an antiapoptotic oncoprotein) and PAX5 (paired box 5 a.k.a. B cell specific activator protein, which is important for B cell development and maintenance of lineage fidelity). The cluster of differentiation (CD) antigen CD5 (hallmark of B1 B cells that mitigates activating signals from the BCR) is variably expressed; a recent study reported 5% to 20% of cases to be positive (usually weakly) for this surface marker. CD10, a membrane metalloendopeptidase that is also known as nephrilysin or common acute lymphoblastic leukemia antigen (CALLA), as well as CD23 and CD103 (ITGA2E-encoded integrin) are mostly absent. The plasmacytoid portion of the tumor cell clone typically expresses cytoplasmic IgM that is secreted into the serum, in conjunction with B cell markers; for example, CD19 and CD45 (protein tyrosine phosphatase, receptor type, C or PTPRC) and plasma cell markers; for example, CD38 (cyclic ADP ribose hydrolase) and CD138 (syndecan 1). This indicates that the cells are arrested at an intermediate plasmablast-like or preplasmacyte-like stage of differentiation. Nuclear immunoreactivity includes IRF4 (interferon regulatory factor 4) and PRDM1 (PR domain containing 1, with ZNF domain, better known as BLIMPI).

In agreement with the flow cytometric pattern described previously, a recent immunohistochemical study of nuclear protein expression of WM cells demonstrated that less mature CD138⁺ PAX5⁺ plasma cells were significantly more abundant in WM than in marginal zone lymphoma (MZL) or plasma cell myeloma (a.k.a. multiple myeloma or MM). Conversely, more mature CD138⁺ IRF4⁺ cells were rare in WM relative to MZL and myeloma [125]. The transcription factor network that governs the peculiar plasmacytoid differentiation arrest of WM cells is poorly understood.

3.2. Immunoglobulin Analysis. DNA sequence analysis of productively rearranged, expressed Ig variable (IgV) genes has provided important clues on the natural history of CLL, SMZL, MCL, and other neoplasms derived from mature B lymphocytes [126–129]. Inspired by these advances, investigators analyzed the variable portion of IgM heavy- and light-chain genes from both patients with WM and individuals with IgM MGUS. In addition to the skewed κ/λ light-chain ratio mentioned previously, research questions included...
the mutational status of IgV genes (germ line versus mutated versus hypermutated), the immune repertoire utilized by WM cell clones (random versus biased usage of \( V_H \) or \( V_L \) gene families and/or individual genes within these families), the ability of WM cells to perform class switch recombination (CSR; i.e., switching of heavy-chain constant region genes from the “unswitched” or “preswitch” \( \mu/\delta \) isotypes to the “switched” or “postsswitch” \( \gamma, \alpha, \) and \( \epsilon \) isotypes), and the propensity of WM to undergo clonal diversification (intracellular heterogeneity). The results of these investigations showed that the great majority of mIgM IgV genes harbor somatic mutations, although the number of mutations was low in many cases. Additionally, there was evidence for nonrandom IgV gene usage; for example, genes from the \( V_H3 \) family were more frequently involved in WM than one would expect by chance. There was little if any support for ongoing diversification of WM cell clones; in other words, the neoplasm appears to be remarkably stable with regard to Ig expression [130–134]. Although WM cells could be coated by some investigators to undergo CSR in vitro, this appeared to take place at a very low level [135] and, with the exception of one well-documented example [136], did not seem to occur in vivo. A recent examination of 59 patients with WM and 64 individuals with IgM MGUS (\( n = 123 \)) reconfirmed the older
studies summarized previously. The productively rearranged VDJ region of IgM was molecularly cloned in 99 of 123 (80%) cases and then analyzed using DNA sequencing: VH genes were mutated in 94 of 99 (95%) cases. The median rate of mutation was 6.7% (6.7 base-substitution changes per 100 nucleotides sequenced), with a range from 2.1% to 14.5%. Compared to normal B cells, genes from subgroup VH3 were overrepresented in both WM and IgM MGUS cells, whereas genes from subgroups VH1 and VH4 were underrepresented. The results were interpreted to mean that WM cells have antigen experience [137]. The nature of the underlying antigens will be discussed in the following two sections.

3.3. Autoimmune and Natural Antibodies. Determination of the immunological specificity of the hallmark monoclonal IgM protein may lead to additional insights into the natural history of WM, because it may reveal the underlying antigens that stimulated WM precursors by virtue of BCR signaling in the course of tumor development. As alluded to in Section 1.3, the clinical presentation of patients with WM or individuals with IgM MGUS sometimes provides clues about the immunological specificity of the associated IgM [138]. This is the case when the immunoglobulin is autoreactive and, therefore, functions as an antibody that can bind to a specific self-antigen and cause autoimmunity. WM has been firmly linked to three autoimmune syndromes designated mixed IgM-IgG cryoglobulinemia (MC) [139], chronic cold agglutinin disease (CAD) [140], and IgM neuropathy [141]. The associated self-antigens include, respectively, the Fc portion of IgG, so-called I/i epitopes on red cells, and neural carbohydrates. However, it is doubtful whether these autoantigens represent the original ligands that induced IgM signaling in WM precursors and, thereby, promoted oncogenesis. Instead, evidence indicates that the original antigens are exogenous in nature, possibly including hepatitis C virus in case of MC, bacterial LPS in case of CAD, and various bacteria and viruses in the neuropathies [138]. This would be in line with our current understanding of the etiology of WM presented in Section 2.2. The literature on WM paraproteins includes numerous case reports on additional mIgM autoantibody specificities, suggesting that the three autoimmune syndromes mentioned previously comprise only the tip of the iceberg. Examples of autoantibodies include reactivity to cytomegalovirus [142] and, as described decades ago by Jan Waldenström himself, to streptolysin-O [143]. This provides additional ammunition for implicating exogenous antigens in WM. Section 4.4 will discuss the possibility that WM-associated autoantibodies, and perhaps many WM-associated IgM paraproteins for which the immunological specificity remains unknown, are in fact natural antibodies [144] produced by natural effector memory B cells. Natural antibodies, which can be readily detected in neonates and young children without prior exposure to pathogen, are immunoglobulins that exhibit low affinity to antigen and polyreactivity to a large number of self and non-self antigens. In conclusion, autoimmune symptoms of patients with WM may be brought about by cross-reactivity of IgM to exogenous and endogenous antigens.

3.4. T-Cell-Selected mIgM. Investigators in Germany have recently come up with an alternative explanation for the origin of WM-associated paraproteins; they proposed that the mIgM is in fact a product of a T-cell-dependent (TD) immune response. They used a relatively new method of Ig analysis called expression cloning [145] to determine the immunological specificity of IgM paraproteins from patients with WM and individuals with IgM MGUS and discovered several common self-antigens dubbed “paraprotein targets” or “paratargs” for short, including a phosphorylated form of paratarg-7, which they termed pP-7. Compared to non-carriers, carriers of pP-7 were found to have a 6.5-fold higher risk for developing IgM MGUS and WM [146], as well as an 8-fold to 13-fold elevation of the risk for IgA/G MGUS and MM [147]. Biochemical studies showed that phosphorylation of P-7 occurred at serine 17 (S17), a residue that is strategically located in the paraprotein-binding epitope of the self-antigen. Analysis of the CD4 T-cell response to both P-7-(S17 not phosphorylated-) derived peptides and pP-7-(S17 phosphorylated-) derived peptides in affected and nonaffected family members demonstrated that pP-7 induced a strong HLA-DQ- and HLA-DR-restricted immune response, but P-7 did not. This suggested that pP-7 confers sustained autostimulation of cognate helper T cells, which, in turn, specifically activate B cells with high-affinity binding to pP-7. These B cells appear to undergo clonal expansion until IgM MGUS is manifest and progresses, in some cases, to frank WM. Preliminary coimmunoprecipitation studies presented at ASH 2012 identified PKCζ (protein kinase zeta) and PP2A (protein phosphatase 2A) as the principal kinase and phosphatase at P-7 S17, respectively. These results indicate that only those pP-7-carrying individuals are at elevated risk of developing WM that have the requisite MHC (major histocompatibility complex) class II haplotype for cognate interaction of antigenic pP-7 peptides and CD4+ T cells. The investigators speculate that this may explain, in part, the different prevalence of IgM MGUS/WM in different ethnic backgrounds. The findings presented previously raise the possibility that WM precursors are generated in TD immune responses.

3.5. Key Points and Future Directions. The immunophenotype of WM is well established (Figure 3), and the autoantibody activity of WM-associated paraproteins is commonly known. Still lacking, however, is a detailed analysis of the immunological specificity of IgM paraproteins with respect to primordial, underlying antigens. This is a difficult area of research, plagued with a host of technical problems that has not been productive in the past. This will hopefully change in the near future as—in addition to expression cloning [145] used in the “paratarg” studies described in Section 3.4—new methods have been developed that lend themselves to identifying and validating specific antigens/haptens recognized by WM-associated mIgM. Epitope-mediated antigen prediction (E-MAP) [148] and high-density peptide microarrays [149] are two promising methods to that end. It is possible that both endogenous (self) antigens and exogenous (microbial) antigens trigger WM. Elucidating the nature of these antigens
is of great relevance for the long-standing, thorny issue of the cellular origin of WM. This will be discussed in depth in the following chapter.

4. Cell of Origin

4.1. WM Precursors May Derive from the IgM+ Memory B-cell Compartment. The immunophenotypic profile of WM cells—in conjunction with the occurrence of somatic mutations in IGV-encoded portions of the IgM paraprotein heavy and light chains—has long been interpreted to mean that WM originates from a mature, antigen-experienced B cell that exit the GC as an atypical IgM+ memory B cell that had engaged the somatic hypermutation (SHM) pathway of antibody affinity maturation but failed to perform CSR in the course of the GC reaction [131]. This view, which implies that the WM precursor is a conventional follicular B cell recruited into a TD immune response, has been challenged by recent progress in our understanding of the IgM+ memory B cell compartment, which appears to be more complex than assumed before. Indeed, new pathways of IgM+ B cell differentiation and memory formation discovered in the past few years [150, 151] prominently include so-called unconventional B cells, such as MZ B cells and B1 B cells, in addition to conventional, follicular B cells often referred to as B2 cells. The newly appreciated complexity of IgM+ memory has raised the bar higher for identifying WM precursors, because it is possible that the precursor cell pool is heterogeneous and gives rise to different subtypes of WM depending on the underlying B cell.

The sources of IgM+ memory B cells and their abundance in spleen and peripheral blood are depicted in Figure 4. It shows that flow cytometric analysis of mature CD19+B-lymphocytes for expression of the memory B cell marker, CD27, identifies approximately 30% of cells as CD27+ memory B cells [152]. CD27 is a member of the TNF receptor superfamily that binds to CD70, a member of the TNF ligand superfamily [152, 153]. The CD27+ compartment is composed equally of “switched” IgM−B cells and “unswitched” IgM+ B cells that have or have not undergone CSR, respectively. The CD27+ IgM+ compartment can be further divided based on expression of surface IgD, an immunoglobulin that is expressed at low levels when B lymphocytes exit the bone marrow and begin to populate peripheral lymphoid tissues but is upregulated and strongly expressed when the cells reach full maturity in situ. Double-positive IgM+IgD+ or “natural effector” cells comprise the bulk of the CD27+IgM+ compartment (99%), whereas single-positive IgM+IgD− or “IgM-only” B cells only represent a minor population (1%)
It seems reasonable to propose that the IgM+ memory compartment (indicated by blue box in Figure 4) contains the elusive WM precursor(s). But even if that was true, the question remains whether WM is derived from an IgM+ IgD− B cell or IgM+ IgD+ B cell. While the former nicely matches the IgM+ IgD− phenotype of a typical WM cell, it is rare to begin with. The latter does not match the WM surface marker profile but is abundant and easily recalled as a WM precursor if one postulates that IgD is downregulated or lost during malignant cell transformation. Consistent with this possibility, a minority of cases (5–10%) weakly expresses IgD (Figure 2), and CD20+ IgM+ IgD+ B cells have been implicated as WM precursors in the past [155]. The biological significance of the IgM+ memory B cell compartment and its principal developmental pathways will be discussed in the following in greater depth.

4.2. B cell Memory Is Long Lived and Includes a Sizeable Fraction of IgM+ Cells. Human memory B cells can survive for decades [156–158]. This is intriguing from a tumor development point of view because longevity can be expected to endow a putative target of neoplastic development with greater opportunities to complete the time-consuming, multistep process of oncogenesis than available for short-lived B cells. The life span of the latter may be insufficient to accumulate all the genetic and epigenetic changes required for fully autonomous, malignant growth. Upon reencounter with the antigen or hapten for which they exhibit immunologic specificity, memory B cells can rapidly proliferate and differentiate into plasma cells that secrete high-affinity antibodies. Memory B cells have classically been defined as antigen-experienced, long-lived IgD− cells that have undergone somatic mutations in their productively rearranged and expressed IgV genes. Additional characteristics include the presentation, on the cell surface, of the memory marker, CD27, and costimulatory and activation markers, including CD80 and CD86 (tandem ligands for CD28 and CD152 on T cells, resp.), as well as CD95 (FAS receptor). In contrast to these markers, the low-affinity IgE receptor, CD23, is downregulated in memory B cells [159, 160].

Recent work from several laboratories has demonstrated that the memory B cell population is phenotypically, functionally, and ontogenetically heterogeneous. Analysis of Ig expression patterns by antigen-binding CD22+ B cells revealed that a surprisingly large proportion of memory cells do not perform CSR of the expressed H chain and, therefore, continue to express IgM. This finding not only demonstrated the existence of IgM+ memory [161, 162], it also raised the question what the benefit for the host might be to maintain these cells for long periods of time. One important answer came from a study in mice, showing that upon secondary challenge with antigen, the IgM and IgG memory subsets displayed differential effector functions: the IgG+ cells rapidly differentiated into plasmablasts, whereas the IgM+ cells reinitiated secondary GC reactions [163]. This suggested that IgM+ cells comprise a durable reserve for humoral immune responses that can be recalled at an indeterminate, later point in life. A related, independent study demonstrated that IgM+ cells were longer lived than their IgG+ counterparts but responded to reencounter with the specific antigen in a different way: the switched memory dominated the secondary immune response (due to its capacity to become activated in the presence of neutralizing serum Ig), whereas IgM+ memory cells did not contribute to this response until after the switched memory cells disappeared and the Ig levels had declined [164]. This result led to the theory that IgM+ memory is “waiting in the wings,” as a backup force of sorts, ready to spring into action when the switched memory fails to clear the antigen but quietly staying in the background when the switched memory is able to take care of the job [164].

4.3. “IgM-only” or IgM+ IgD− Memory B cells. Features, subtypes, and developmental history of IgM+ memory B cells have been worked out in detail in the past few years (Figure 4, bottom). B cell immunologists now divide IgM+ memory B cells into two compartments: “natural effector” cells, which will be described in Section 4.4, and “IgM-only” cells, which will be described here. Evidence provided by a Dutch group indicates that “IgM-only” or CD27+ IgM+ IgD− memory B cells originate from primary GC responses. Building on the widely accepted paradigm that extensive antigen-induced cell proliferation and somatic hypermutation (SHM) are hallmarks of memory B cells, the Dutch investigators developed two nifty molecular assays—called KREC (Igκ restriction enzyme hot-spot mutation) and IgκREHMA (Igκ restriction enzyme hot-spot mutation)—that are able to generate good estimates of a B cell’s replication history (i.e., number of cell divisions) and SHM history (i.e., number of somatic mutations in IgV genes), respectively [165]. KREC is a qPCR assay for determining the ratio of genomic coding and signal joints formed in consequence of genetic inactivation of the IGK locus, which is accomplished by chromosomal rearrangements that delete the IGK constant region gene, Cκ, together with the downstream IGK enhancer, 3′Eκ [165]. IgκREHMA is a DNA spectratyping assay that determines the mutational load in CDRI (complementarity determining region 1) of the IGKV3-20 gene, which has been validated as a reliable indicator of overall SHM activity in expressed Ig genes in vivo. The Dutch investigators found that “IgM-only” B cells had a replication and SHM history in line with GC B cells, suggesting that CD27+ IgM+ IgD− B cells are offspring of follicular B cells that underwent SHM-mediated affinity increases in their μH chains in the course of a primary GC response but exited the GC prior to undergoing isotype switching. “IgM-only” memory B cells match the IgM+ IgD− phenotype of frank WM and have been repeatedly shown to undergo expansion in patients with autoimmune diseases [166, 167]—a putative driver of WM. This backdrop suggests that the natural history of IgM MGUS and WM may begin with “IgM-only” memory B cells.
4.4. “Natural Effector” or IgM\(^+\)IgD\(^-\) Memory B cells. CD27\(^+\)IgM\(^+\) memory B cells that coexpress IgD outnumber their IgD\(^-\) counterparts in peripheral blood and spleen by approximately two orders of magnitude. CD27\(^+\)IgM\(^+\)IgD\(^-\) or “natural effector” B cells comprise a heterogeneous compartment that includes developmentally primitive, unconventional B cells derived from MZ B cells or B1 B cells [150, 151]. The “primitive” origin notwithstanding, natural effector B cells are thought to be bona fide memory cells based on three lines of evidence. First, they express high levels of activation/costimulation molecules such as CD80, CD86 (also known by the archaic term Bgp-95 [168]), and TACI (tumor necrosis factor [TNF] receptor superfamily, member 13B [TNFRSF13B]). CD80 and TACI are of special interest because they induce cellular signal transduction pathways dependent on myeloid differentiation primary response 88 (MYD88). CD86, which associates with lymphocyte antigen 86 (LY86 a.k.a. MD-1) to form a cell surface receptor complex that belongs to the Toll-like receptor (TLR) family, works in concert with TLR4 to regulate B cell activation in response to lipopolysaccharide (LPS), a membrane constituent of Gram-negative bacteria. TACI regulates humoral immunity by virtue of interacting with two TNF family ligands, BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand). BAFF [169]—also known as TNF ligand superfamily, member 13B (TNFSF13B), B-lymphocyte stimulator (BLYS), TNF- and APOL-related leukocyte expressed ligand (TALL1) [170], or cluster of differentiation 257 (CD257)—is a cytokine that acts as a potent activator of B cells and plays an important role in the proliferation and differentiation of B cells. APRIL—also referred to as tumor necrosis factor ligand superfamily, member 13B (TNFSF13B), B-lymphocyte stimulator (BLYS), TNF- and APOL-related leukocyte expressed ligand (TALL1) [170], or cluster of differentiation 256 (CD256)—is important for the long-term survival of plasma cells in the bone marrow [171].

The BAFF/APRIL/TACI/MYD88 axis is important for the development of natural effector cells and their function as memory cells. Second, natural effector B cells appear to be selected against inherently autoreactive VH domains, a general feature of memory B cells. Consistent with that, the cells have an extensive replication history compared to naive B cells (using the KREC assay) and exhibit SHM profiles of Ig heavy and light variable genes that are characterized by high R/S (replacement to substitution) ratios in H chain CDRs (IgκREHMA assay) [154]. Natural effector B cells were found to have proliferated somewhat less vigorously (7 cell divisions on average) than GC B cells (9 divisions), but the mutational load in GHV was comparable in the two cell types. This result lent additional support to the contention that a substantial fraction of CD27\(^+\)IgM\(^+\)IgD\(^-\) memory B cells is generated outside the GC, using a pathway of SHM that operates independently of the GC reaction. Third, a recently reported high-throughput analysis of VH\(_3\) sequences from blood samples of three adult donors [172] found major differences in the immunological repertoire of CD27\(^+\)IgM\(^+\)IgD\(^-\) B cells and IgG\(^-\) or IgA\(^-\) B cells. Compared to switched B cells, natural effector B cells exhibited a twofold higher usage of VH\(_3\) but a 20-fold lower usage of VH\(_{11}\). The marked bias for (V\(_{H}3\)) and against (V\(_{H}1\)) heavy-chain gene families is strikingly similar to that seen in WM, raising the possibility that the same selective force might shape the repertoire of natural effector and WM cells [172]. These findings lend credence to the proposal that WM is derived from natural effector B-memory cells.

5. MYD88 Signaling Links Natural Effector Memory and WM

5.1. Genetic Defects in the MYD88-IRAK4-TIRAP Pathway Result in Loss of IgM\(^+\)IgD\(^-\) Memory B cells. Inherited immunodeficiency disorders may be crudely considered experiments of Mother Nature that permit us to glean unique insights into pathways of immunity that would be difficult to dissect in immunocompetent individuals. This is particularly true for IgM memory, the understanding of which has been greatly aided by the examination of patients that harbor rare genetic defects in immune genes governing memory responses. An important early clue was obtained in investigations of patients with deficiencies in GC formation due to lack of CD40-CD154 signaling during cognate B- and T-cell interaction at the outset of the GC reaction. The number of CD27\(^+\)IgM\(^+\)IgD\(^-\) memory B cells was significantly reduced in these patients, yet the cells did not completely disappear from peripheral blood [173–175]. This finding indicated that CD27\(^+\)IgM\(^+\)IgD\(^-\) memory B cells are normally generated using both GC-dependent and -independent pathways. Postulating that the latter include pattern recognition receptors of the Toll-like receptor (TLR) family, a recent study analyzed peripheral B cell subsets in patients exhibiting genetic defects in TLR signaling. Inherited deficiencies along this line affected (1) one of ten TLRs expressed in human beings: TLR3, (2) three different adapter proteins: MYD88, toll-interleukin 1 receptor domain containing adaptor protein (TIRAP), and toll-like receptor adaptor molecule 1 (TICAM a.k.a. C. elegans unc-93 homolog B1 or UNC-93B), and (3) a protein kinase involved in downstream signal transduction: interleukin-1 receptor-associated kinase 4 (IRAK4). In order to put the biological consequences of these genetic defects into perspective, it is important to realize that, first, all TLRs except TLR3 rely on MYD88 and IRAK4 for downstream signaling and, second, TIRAP is additionally important for signaling induced by TLR4 homodimers and the heterodimers TLR2 forms with TLR1, TLR6 and, possibly, TLR10. This is schematically depicted in Figure 5(a). The analysis revealed that loss of MYD88, IRAK4, and TIRAP function led to significant reductions in CD27\(^+\)IgM\(^+\)IgD\(^-\) memory B cells, but left their IgD\(^-\) counterparts unchanged (Figure 5(b)). The discovery of MYD88-TIRAP-IRAK4 as the first genetic pathway specifically required for CD27\(^+\)IgM\(^+\)IgD\(^-\) memory [176] lends support to the concept that pattern recognition receptors signaling through MYD88 homodimers (Figure 5(a), right) or MYD88/TIRAP heterodimers (Figure 5(a), left).
promote the homeostatic maintenance of B cells that do not depend on T-cell help for activation and survival. Sections 5.2 and 5.3 will argue that the decrease in circulating MYD88-TIRAP-IRAK4-dependent CD27+ memory B cells shown in Figure 5(b) may be the result of impaired survival and immunological responsiveness of MZ and B1 cells [154, 176]—even though alternative explanations (Section 5.4) exist.

5.2. **IgM<sup>+</sup>IgD<sup>−</sup> Memory B cells May Be Derived from MZ B cells.** MZ B cells are good candidates for MYD88-TIRAP-IRAK4-dependent memory B cells for the following reasons. First, unlike laboratory mice in which MZ B cells express germline IGV genes, reside in the splenic marginal zone, and do not recirculate [166], MZ B cells in human beings carry mutations in the IGV-encoded portions of the B cell receptor and recirculate in the blood stream [166]. The mutations in IGV genes appear to be of the more limited “extrafollicular variety” [154, 166] and are probably caused by a mechanism that involves recently discovered pathways of AID-dependent but T-cell- and GC-independent SHM [179]. Consistent with the moderate mutational load in their expressed IGV genes, MZ B cells contain molecular footprints of past proliferation in an extrafollicular environment [154, 173, 180, 181]. Prenatal studies have lent additional support to the notion that MZ B cells are able to mutagenize IGV genes in the absence of GCs and independent of stimulation with antigen [154, 173, 180, 181]. Second, the splenic marginal zone may be involved in induction of IGV mutations because it contains foci of proliferating, clonally related B cells that express AID [182, 183]. These B cells make use of a specialized TI pathway of SHM that involves the recognition of commensal antigens presented on neutrophil extracellular traps (NETs) formed by neutrophils in the marginal or perimarginal zone. Neutrophils of this sort have been designated neutrophil B cell helper (NBH) cells [183].

![Diagram of TLR signaling](image)

**Figure 5: MYD88—an intriguing link between WM and natural effector IgM<sup>+</sup> memory cells.** (a) In normal B-lymphocytes and other cells of the immune system, MYD88 functions as a signaling adaptor protein that activates the nuclear factor κB (NF-κB) pathway following stimulation of Toll-like receptors (TLRs) and receptors for IL-1 and IL-18 (not shown). MYD88 coordinates the assembly of a supramolecular signaling complex that contains members of the IRAK (interleukin-1 receptor-associated kinase) family of serine-threonine kinases. Following TLR ligand binding, MYD88 is recruited to the cell membrane-bound receptor complex, leading to recruitment of IRAK4, which activates IRAK1-dependent activation of tumor necrosis factor receptor-associated factor 6 (TRAF6) affects NF-κB activation via phosphorylation of IκBα and execution of the NF-κB-dependent gene regulation program. TIRAP is an additional adapter protein involved in TLR4 and TLR2 signaling (see Section 5.1 for details). (b) Genetic loss of MYD88, IRAK4, and TIRAP function leads to significant reductions in CD27+ memory B cells, indicating that the MYD88-TIRAP-IRAK4 pathway is essential for homeostatic maintenance of the natural effector memory. (c) WM cells harbor the highly recurrent, gain-of-function L265P exchange in the MYD88 adaptor protein, indicating that WM depends on elevated TLR signaling. This is intriguing in light of the findings depicted in (b) and suggests that WM is derived from natural effector memory B cells.

![Diagram of TLR signaling](image)
express TACI and BAFFR and are hyperresponsive to signals that mimic T-cell activation [186]. They also reported that compared to switched MZA B cells, IgM\(^{+}\) MZA B cells respond poorly to inducers of plasmacytic differentiation in vitro [187]. This is reminiscent of the lymphoplasmacytic phenotype of WM cells, which appear to respond poorly to inducers of plasmacytic differentiation in vivo. In sum, a considerable body of circumstantial evidence suggests that MZ B cells contribute to the MYD88-TIRAP-IRAK4-dependent natural effector memory B cell pool under normal steady-state conditions.

### 5.3. IgM\(^{+}\) IgD\(^{−}\) Memory B cells May Be Derived from B1 Cells

A newcomer among human B cell subsets that is still somewhat controversial but potentially important for the MYD88-TIRAP-IRAK4-dependent natural effector memory B cell population is the B1 lymphocyte—the long-searched equivalent of the mouse B1 B cell lineage responsible for most of the spontaneous IgM production in mice. The human B1 subset, identified as CD27\(^{+}\) IgD\(^{−}\) CD43\(^{+}\), displays typical characteristics of “primitive” or “innate-like” B cells, including tonic BCR signaling, low level of spontaneous IgM\(^{+}\) plasma cell production, and capacity to drive allogenic T-cell proliferation [188, 189]. B1 B cells perform a variety of biological functions (e.g., antigen presentation and priming of T-cells), but their principal role is the secretion of natural antibodies (prominently including IgM) in the absence of exogenous antigenic stimulation [190]. Natural antibodies are low-affinity, polyreactive immunoglobulins that use \(\mu\) or \(\alpha\) H chains that typically harbor only a minimal number of somatic mutations and few if any insertions of nontemplated nucleotides at V(D)J junctions [191]. Natural antibodies provide instant defense against invading pathogens, and also prevent autoimmunity by virtue of inducing a non-inflammatory, nonimmunogenic clearance pathway for altered self-antigens including apoptotic bodies [192]. Curiously enough, the CD27\(^{+}\) IgD\(^{−}\) CD43\(^{+}\) subset was recently shown to comprise about 40% of CD27\(^{+}\) B cells in adults, a proportion quite similar to the \(~50\%\) CD27\(^{+}\) IgD\(^{−}\) IgM\(^{+}\) cells indicated in Figure 2. This has raised the question as to whether B1 B cells and natural effector B cells are largely overlapping and what the true contribution of MZ B cells to the natural effector memory cell compartment might be. Although it may be appealing from a conceptual point of view to essentially equate circulating B1 B cells with the equivalent of the mouse B1 B cell lineage responsible for most of the spontaneous IgM production in mice [193, 194], Be this as it may, the possibility that B1 B cells make a significant contribution to CD27\(^{+}\) IgM\(^{+}\) IgD\(^{−}\) memory cannot be rejected.

### 5.4. Alternative Sources of IgM\(^{+}\) IgD\(^{−}\) Memory B cells

Despite the arguments in favor of MZ B and B1 B cells presented previously, the occurrence of somatic mutations in IGV genes expressed in CD27\(^{+}\) IgM\(^{+}\) IgD\(^{−}\) memory B cells has fostered an alternative interpretation of the origin of these cells. Just like CD27\(^{+}\) IgM\(^{+}\) IgD\(^{−}\) memory B cells, it has been proposed that CD27\(^{+}\) IgM\(^{+}\) IgD\(^{−}\) memory B cells derive from follicular B cells that have prematurely aborted the GC where they underwent moderate levels of SHM but avoided CSR [195]. Although this interpretation does not flat-out reject the theory that MZ B- and B1 B cells constitute separate, GC-independent B cell diversification pathways [196], it questions the role of innate-like B cells in the formation and maintenance of the natural effector memory B cell compartment [197]. To further complicate the picture, it is possible that additional types of innate-like B cells exist that are able to feed the natural effector memory B cell compartment. A case in point is the CD21\(^{low}\)CD23\(^{−}\)CD38\(^{low}\)CD86\(^{hi}\) B cell that expresses IgM and IgD with minimal or no mutations and has been repeatedly described to expand under nonphysiological conditions [198]. These cells were first identified in patients with common variable immunodeficiency (CVID), especially in those with splenomegaly and granulomatous disease [199], but later found to be abnormally elevated in peripheral tissues, such as the bronchoalveolar space [198]. In theory, it is easy to imagine that different types of B cells and biological pathways of B cell development overlap to shape the immune repertoire of natural effector memory B cells. Slow, ongoing induction of SHM via T1 pathways triggered by signals from commensal microbial products may cooperate with immunization- or infection-dependent stimuli that rely on both extrafollicular TI and follicular TD pathways. The combination of these pathways would ensure the development of a highly diversified repertoire of ready-to-use innate-like natural effector cells [198], some of which may go on to become precursors of WM.

### 5.5. Constitutive Active MYD88 Signaling in WM

No matter what the true origin of MYD88-TIRAP-IRAK4-dependent natural effector memory B cells might be, the finding that these cells are largely dependent on MYD88 signaling provides an intriguing link to the natural history of WM. MYD88 was put at center stage of WM research when pioneering work at the Dana-Farber Cancer Institute, Boston, MA, demonstrated that the great majority of IgM\(^{+}\) LPL contains a specific somatic point mutation in the protein-encoding portion of the MYD88 gene, which replaced a leucine (L) residue at position 265 of MYD88 with a proline (P) residue. The highly recurrent exchange was uncovered by next-generation whole-genome sequencing and then confirmed using conventional Sanger sequencing [99]. The mutation and the resulting tumor allele are designated L265P and MYD88\(^{L265P}\) respectively. L265P resides in the TIR domain of the MYD88 protein, which interacts with TIR domains of various membrane receptors involved in innate immune responses, such as TLRs, IL-1R, and IL-18R. The occurrence of the L265P mutation has been confirmed in independent studies, reporting incidence rates in WM patients that range from 70% to detection in all cases [200–203]. Evidence indicates that MYD88\(^{L265P}\) is a gain-of-function mutation, causing elevated activity of the adaptor protein, MYD88, in TLR and interleukin signaling [204]. Following receptor stimulation, MYD88 is recruited to the activated receptor complex as a homodimer, which then complexes with interleukin-1 receptor-associated kinase (IRAK) 4 to activate IRAK1 and
IRAK2 [177, 178]. This leads to IRAK1-dependent phosphorylation of tumor necrosis factor receptor–associated factor 6 (TRAF6), which results in nuclear factor κB (NF-κB) activation via IkBx phosphorylation. NF-κB is essential for growth and survival of WM cells. Inhibition of MYD88 signaling inhibits L265P-mutated WM cells by blocking IkBx phosphorylation and nuclear translocation of transcriptionally active NF-κB dimers [203]. Bruton tyrosine kinase also contributes to MYD88-dependent activation of NF-κB in WM cell that harbors the L265P mutation [203]. It is interesting to note that—in accordance with the distinction of specific “WM genes” and “general B-lymphoma predisposition alleles” outlined in Section 2.3—MYD88L265P should be viewed as the latter. Thus, MYD88L265P was detected in B-CLL and ABC-type diffuse large B-cell lymphoma and later on also found in primary central nervous system lymphoma and mucosa-associated lymphoid tissue lymphoma [205–209]. Although the oncogenic MYD88L265P allele is neither specific for WM nor was it first discovered in patients with WM, in no case does it occur as consistently as in WM. This defines a clear path forward for improving the outcome of WM.

5.6. Key Points and Future Directions. Unlike “IgM-only” IgM+IgD− memory B cells, “natural effector” IgM+IgD+ memory B cells depend on MYD88-IRAK4-TIRAP signaling for development and/or survival. Natural effector B cells are probably derived from MZ and B1 B cells, but opposing views that consider follicular and other types of B cells also exist. Regardless how this puzzle resolves, the disappearance of natural effector cells under conditions of MYD88 deficiency and the strong selection for the MYD88L265P gain-of-function allele in WM support the hypothesis that WM may originate from primitive, natural antibody-producing B-lymphocytes that are dependent on MYD88 signaling for homeostatic maintenance under normal conditions but highly susceptible to neoplastic development upon acquisition of enhanced MYD88 signaling due to the L265P mutation. Laboratory mice may lend themselves to testing the possibility that this mutation confers a strong selective advantage for tumor development. Of great relevance to that end is the finding that L265P occurs at a residue that has been invariant (unchanged) over eons of biological evolution. Thus, L265 has been conserved across the animal kingdom, ranging from frogs to rodents all the way to human beings, indicating that this residue is crucial for MYD88 function.

6. Recapitulating Human WM in Laboratory Mice

6.1. The Laboratory Mouse Is the Premier Model Organism for Research on Human WM. Because of the low incidence, indolent clinical course, and a variety of other reasons, WM has been woefully neglected in the biomedical research arena compared to its closely related but more prevalent or aggressive cousins among mature B cell and plasma cell neoplasms, such as CLL and MM. The logical consequence of persistent underfunding of WM research is the existence of major knowledge gaps in our understanding of the pathophysiology of the disease. Closing these gaps may require the development of good experimental model systems of human WM. The laboratory mouse lends itself to that purpose because it is the undisputed premier model organism for human diseases including cancer. It also serves as the workhorse of cancer genetics. Among the many advantages the laboratory mouse affords is the close genetic relationship to man; that is, virtually all genes in human beings have a homologue with comparable function in mouse. Additionally, methods for manipulating the mouse genome, including gene targeting for “knocking” mouse genes “out” and human genes “in,” have been perfected. This permits us to “humanize” mice such that genetically engineered strains of mice are able to mimic human disease manifestations more accurately than ever before. On the other hand, the inherent challenges of modeling a complex human disease like WM in laboratory mice should not be underestimated. Despite the many strengths of the “mighty mouse,” it is currently not possible to fully recapitulate human WM in laboratory mice, neither with regard to reproducing WM-typical somatic mutations in appropriate target cells (genocopy of human WM) nor with regard to reproducing the complete spectrum of WM-associated clinicopathologic features and laboratory findings (phenocopy of human WM). The sections below will attempt to summarize the efforts of the biomedical research community to model human WM in mice. This can be conceptually divided in “first generation” xenotransplantation models of WM and “second generation” transgenic models. The latter yield WM-like tumors that develop de novo (spontaneously) in the presence of a fully functional, innate, and adaptive immune system, similar to tumor development in human beings.

6.2. Xenotransplantation Models of WM. The first approach to modeling human WM in laboratory mice relied on in vivo propagation of human tumor cells in immunocompromised mice. In these human–mouse xenotransplantation models, fully transformed tumor cells—either obtained from patients with WM or in vitro cultures of permanent WM cell lines—are transferred to severe combined immunodeficiency (SCID) mice, which provide the nesting ground for tumor cell engraftment. The SCID mice may harbor subcutaneous implants of human bone (SCID-hu) [210]—or, in the case of the still more severely immunocompromised nonobese diabetic (NOD) SCID strain, intramuscular implants of human bone (NOD-SCID-hu) [211]—to provide the kind of microenvironment (hematopoietic bone marrow) WM cells prefer and are used to (Figure 6(a)). The WSU-WM-SCID model [212, 213], which was used to evaluate the experimental drug XK469 [214], and related models have made and continue to make valuable contributions to the preclinical assessment of WM therapeutics. However, technical and logistic barriers have prevented these models from having significant impact on the process of WM drug discovery; that is, they are not extensively used in preclinical trials and have not gained wide acceptance in the pharmacological industry. Another shortcoming is that, by their very nature, SCID models are not suitable for studies on tumor development.
Figure 6: Mouse models of human WM. (a) Xenotransplantation models rely on the propagation of human WM cells in SCID mice that may contain human bone (blue) as a nesting ground for incoming tumor cells. (b) Three examples of strains of mice that are prone to WM-like tumors. Tumor development in NSEV mice is dependent on insertional somatic mutagenesis affected by an infectious ecotropic murine leukemia virus. See Section 6.3 for details. (c) Generation of strain C.II6/BCL2/AIDnull mice, an IWMF-sponsored project in the laboratory of the author of this paper. The compound transgenic mouse strain combines two independently developed oncogenes, H2-L1−IL6 (hereafter called IL6) and EpsV-Bcl2-2-22 (hereafter called BCL2), on the genetic background of AID-deficient BALB/c (c) mice. Strain C is uniquely susceptible to late-stage B cell and plasma cell tumors [219, 220] due to a complex genetic trait that includes hypomorphic (weak efficiency) alleles of genes encoding the cell-cycle inhibitor, p16INK4a [221], and the FKBP12 rapamycin-associated protein, Frap [222], and the absence of the interferon-inducible gene, Mndal [223]. The scientific rationale for using the IL6 transgene is strong and includes the following considerations. IL-6 is a pro-inflammatory cytokine that impacts many blood cancers [224], including Hodgkin lymphoma [225], non-Hodgkin lymphoma [226] and myeloma [227, 228]. In human WM, IL-6 has long been recognized as a major growth, differentiation, and survival factor. In mice, IL-6 is firmly linked to inflammation-dependent plasmacytoma (PCT) induced by intraperitoneal injection of pristane [229]. This treatment provokes the formation of inflammatory granulomas, a rich source of IL-6 at the site of tumor development [230]. Critical for a null allele of BCL2 is the use of mice carrying the IL6/BCL2/AID transgene [231], as it demonstrates the derivation of this cell line from tumor tissue of a patient with WM. MWCL-1 cells produce IgMα and exhibit an immunophenotype that is fully consistent with WM: CD19+ CD20+ CD27+ CD38+ CD138+. Like many other continuous human cancer cell lines, MWCL-1 cells are deficient for the p53 tumor suppressor: one copy of the p53-encoding gene, TP53, is deleted, whereas the second copy is mutated. Importantly, MWCL-1 cells harbor the mutant MYD88L265P protein, the hallmark of WM described in Section 5.5. MWCL-1 has not only served as blueprint for generating a valuable additional WM cell line very recently [218], it also has rekindled interest in the research community to employ xenotransplantation models for preclinical studies of new WM drugs.
lymphomas with lymphoplasmacytic features that developed in BALB/c mice deficient in Fas signaling (C.Lpr/Gld) [255, 256], strain NSF.V mice congenic for ecotropic murine leukemia virus (MuLV) [257, 258], and compound transgenic mice in which the Trp53-encoded tumor suppressor, p53, had been specifically inactivated in mature B cells [259] (Figure 6(b)). The strains of mice mentioned previously are available for further improvement, a priority of which may be the introduction of the mutant MYD88<sup>L<sub>265P</sub></sup> allele. The potential promise of crossing in MYD88<sup>L<sub>265P</sub></sup> has been underlined by a recent study showing that autoantibody production in transgenic mouse models of human systemic lupus erythematosus (SLE) depends on MYD88 [260]. Taking advantage of lupus-prone MRL.Fas<sup>−/−</sup> mice in which MYD88 had been selectively inactivated in B cells, the investigators showed that self-reactive antibodies did not arise when MYD88 signaling was abrogated in B cells [261]. The results suggested that transgenic mice that exhibit elevated MYD88 signaling in B cells due to cell lineage-restricted expression of MYD88<sup>L<sub>265P</sub></sup> will be prone to increased autoimmunity followed by formation of WM-like lymphoma. This hypothesis warrants testing. In the author's laboratory, WM-like tumors have repeatedly been observed in mice that carried human IL6 [234] or BCL2 [262] transgenes, although the findings were never highlighted in the publications as these were focused on “switched” IgG<sup>+</sup> or IgA<sup>+</sup> tumors. The findings led to a research project sponsored by the International Waldenstrom's Macroglobulinemia Foundation (IWMF). The project is aimed at generating compound transgenic IL6/BCL2/AID<sup>−/−</sup> mice designed to recapitulate important features of human WM (Figure 6(c)). The rationale for this approach includes our unpublished finding that IL-6 and BCL-2, two key players in human WM (Figure 2), collaborate effectively in neoplastic B cell development in mice. Also included is the expectation that the transfer of these oncogenes to a background that is genetically deficient for AID (activation-induced cytidine deaminase) blocks IL-6/BCL2-driven tumor development at the IgM<sup>+</sup> stage. This is because AID is required for CSR. The outcome of this ongoing investigation notwithstanding, there is good reason to be optimistic that designer models of human WM are feasible. Models of this sort will not only permit us to study different stages of tumor progression, including the transition from IgM MGUS to frank WM, but also facilitate the design and testing of new WM interventions.

6.4. Key Points and Future Directions. Accurate transgenic mouse models, in which WM-like neoplasms develop with short onset (short tumor latency), high genetic penetrance (high tumor incidence), and a predictable and reproducible tumor pattern, are important research tools for furthering our understanding of the natural history of the disease, particularly with regard to tumor initiation and promotion. Designated mouse models of WM may also be helpful for evaluating new approaches to WM treatment and prevention, including selective small-molecule inhibitors of IRAK and Bruton’s tyrosine kinases aimed at dampening MYD88 signaling.

Abbreviations

AID: Activation-induced cytidine deaminase
BCL2: B cell leukemia 2 gene
BCL-2: B cell leukemia 2 oncoprotein
CLL: Chronic lymphocytic leukemia
CSR: Class switch recombination
GC: Germinal center
HSV: Hyperviscosity syndrome
Ig: Immunoglobulin
IgH: Immunoglobulin heavy chain
IgM: Immunoglobulin M
IgV: Immunoglobulin variable gene
IL6: Interleukin 6 gene
IL-6: Interleukin 6 gene product (cytokine)
LPC(s): Lymphoplasmacytic cell(s)
LPL: Lymphoplasmacytic lymphoma
MCL: Mantle cell lymphoma
MGUS: Monoclonal gammopathy of undetermined significance
MM: Multiple myeloma
mlgM: Monoclonal immunoglobulin M, IgM paraprotein, IgM spike
MZL: Marginal zone lymphoma
PC(s): Plasma cells
SHM: Somatic hypermutation
SMZL: Splenic marginal zone lymphoma
TI: T-cell independent
TD: T-cell dependent
WM: Waldenström macroglobulinemia.

Acknowledgments

I wish to thank Ms. Suzanne Herms, Chair, Publications Committee, International Waldenström's Macroglobulinemia Foundation (IWMF), and Dr. Van S. Tompkins, University of Iowa Carver College of Medicine, for reading the manuscript and making valuable suggestions. This work was funded, in part, by research grants 2010-1 from the IWMF and R01CA151354 from the NCI/NIH.

References

[1] E. Campo, S. H. Swerdlow, N. L. Harris, S. Pileri, H. Stein, and E. S. Jaffe, “The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications,” Blood, vol. 117, no. 19, pp. 5019–5032, 2011.
[2] E. D. Remstein, C. A. Hanson, R. A. Kyle, J. M. Hodnefield, and P. J. Kurtin, “Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom’s macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells,” Seminars in Oncology, vol. 30, no. 2, pp. 182–186, 2003.
[3] P. Lin, S. Hao, B. C. Handy, C. E. Bueso-Ramos, and L. J. Medeiros, “Lymphoid neoplasms associated with IgM paraprotein: a study of 382 patients,” American Journal of Clinical Pathology, vol. 123, no. 2, pp. 200–205, 2005.
[4] S. S. Sahota, R. Garand, R. Mahroof et al., “V(H) gene analysis of IgM-secreting myeloma indicates an origin from a memory
cell undergoing isotype switch events,” *Blood*, vol. 94, no. 3, pp. 1070–1076, 1999.
[5] A. Fadi and D. E. Taylor, “The lung and Waldenström's macroglobulinemia,” *Southern Medical Journal*, vol. 91, no. 7, pp. 681–685, 1998.
[6] J. A. Rosenthal, W. J. Curran, and S. J. Schuster Jr., “Waldenström's macroglobulinemia resulting from localized gastric lymphoplasmacytoid lymphoma,” *American Journal of Hematology*, vol. 58, no. 3, pp. 244–245, 1998.

[7] R. R. Doshi, R. Z. Silkiss, and R. K. Imes, “Orbital involvement in Bing-Neel syndrome,” *Journal of Neuro-Ophthalmology*, vol. 31, no. 1, pp. 94–95, 2011.
[8] F. Fintelmann, R. Forghani, P. Schaefer, E. Hochberg, and F. Hochberg, “Bing-Neel Syndrome revisited,” *Clinical Lymphoma and Myeloma*, vol. 9, no. 1, pp. 104–106, 2009.

[9] M. J. Stone, “Waldenström's macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia,” *Clinical Lymphoma and Myeloma*, vol. 9, no. 1, pp. 97–99, 2009.
[10] H. C. Kwaan and A. Bongu, “The hyperviscosity syndromes,” *Seminars in Thrombosis and Hemostasis*, vol. 25, no. 2, pp. 199–208, 1999.
[11] M. A. Gertz, “Waldenström Macroglobulinemia: 2012 update on diagnosis, risk stratification, and management,” *American Journal of Hematology*, vol. 87, no. 5, pp. 504–510, 2012.

[12] B. J. Camp and C. M. Magro, “Cutaneous macroglobulinosis: a case series,” *Journal of Cutaneous Pathology*, vol. 39, no. 10, pp. 962–970, 2012.
[13] K. E. Spicknall, L. E. Dubas, and D. F. Mutasim, “Cutaneous macroglobulinosis with monotypic plasma cells: a specific manifestation of Waldenström macroglobulinemia,” *Journal of Cutaneous Pathology*, vol. 40, no. 5, pp. 440–444, 2013.

[14] G. A. M. Veltman, S. Van Veen, J. C. Kluin-Nelemans, J. A. Bruijn, and L. A. Van Es, “Renal disease in Waldenström's macroglobulinaemia,” *Nephrology Dialysis Transplantation*, vol. 12, no. 6, pp. 1256–1259, 1997.

[15] V. G. Genersch, X. Leliev, F. Provot, F. Moulougnet, and D. Buob, “Cast nephropathy and light-chain deposition disease in Waldenström macroglobulinemia,” *American Journal of Kidney Diseases*, vol. 60, no. 3, pp. 487–491, 2012.

[16] M. A. Gertz, G. Merlini, and S. P. Teun, “Amyloidosis and Waldenström's macroglobulinemia,” *Hematology*, pp. 257–282, 2004.

[17] J. Gardyn, A. Schwartz, R. Gal, U. Lewinski, D. Kristj, and A. M. Cohen, “Waldenström's macroglobulinemia associated with AA amyloidosis,” *International Journal of Hematology*, vol. 74, no. 1, pp. 76–78, 2001.
[18] W. Pruzanski and K. H. Shumak, “Biologic activity of cold-reacting autoantibodies (Second of two parts),” *New England Journal of Medicine*, vol. 297, no. 11, pp. 583–589, 1977.

[19] W. Pruzanski and K. H. Shumak, “Biologic activity of cold-reacting autoantibodies (First of two parts),” *New England Journal of Medicine*, vol. 297, no. 10, pp. 538–542, 1977.

[20] A. Simon, B. Asli, M. Braun-Falco et al., “Schnitzler's syndrome: diagnosis, treatment, and follow-up,” *Allergy*, vol. 68, no. 5, pp. 562–568, 2013.

[21] A. H. Ropper and K. C. Gorson, “Neuropathies associated with paraproteinemia,” *New England Journal of Medicine*, vol. 338, no. 22, pp. 1601–1607, 1998.

[22] J. C. Brovet, J. P. Clauvel, and F. Danon, “Biologic and clinical significance of cryoglobulins. A report of 86 cases,” *American Journal of Medicine*, vol. 57, no. 5, pp. 775–788, 1974.

[23] E. M. Ocio, J. M. Hernández, G. Mateo et al., “Immunophenotypic and cytogenetic comparison of Waldenström's macroglobulinemia with splenic marginal zone lymphoma,” *Clinical Lymphoma*, vol. 5, no. 4, pp. 241–245, 2005.

[24] M. Mateo, M. Mollejo, R. Villuendas et al., “7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma,” *American Journal of Pathology*, vol. 154, no. 5, pp. 1583–1589, 1999.

[25] J. I. Chacón, M. Mollejo, E. Muñoz et al., “Splenic marginal zone lymphoma: clinicopathological and prognostic factors in a series of 60 patients,” *Blood*, vol. 100, no. 5, pp. 1648–1654, 2002.

[26] C. Thebieumont, V. Nasser, P. Felman et al., “Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis,” *Blood*, vol. 103, no. 7, pp. 2727–2737, 2004.

[27] H. C. Kluin-Nelemans, E. Hoster, O. Hermine et al., “Treatment of older patients with mantle-cell lymphoma,” *The New England Journal of Medicine*, vol. 367, pp. 520–531, 2012.

[28] J. Vaandragers, E. Schuurings, E. Zwikstra et al., “Direct visualization of dispersed 1q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization,” *Blood*, vol. 88, no. 4, pp. 1177–1182, 1996.

[29] J. Li, F. Gaillard, A. Moreau et al., “Detection of translocation t(11;14)(q13;32) in mantle cell lymphoma by fluorescence in situ hybridization,” *American Journal of Pathology*, vol. 154, no. 5, pp. 1449–1452, 1999.

[30] O. Annibali, M. T. Petrucci, P. Del Bianco et al., “IgM multiple myeloma: report of four cases and review of the literature,” *Leukemia and Lymphoma*, vol. 47, no. 8, pp. 1565–1569, 2006.

[31] D. E. Reece, D. H. Vesole, S. Shrestha et al., “Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective cibmtr study,” *Clinical Lymphoma, Myeloma and Leukemia*, vol. 10, no. 6, pp. 458–463, 2010.

[32] R. G. Owen, A. G. Bynoe, A. Varghese, R. M. de Tute, and A. C. Rawstron, “Heterogeneity of histological transformation events in Waldenström's macroglobulinemia (WM) and related disorders,” *Clinical Lymphoma, Myeloma & Leukemia*, vol. 11, no. 1, pp. 176–179, 2011.

[33] M. Björkholm, E. Johansson, D. Papamichael et al., “Patterns of clinical presentation, treatment, and outcome in patients with Waldenström's macroglobulinemia: a two-institution study,” *Seminars in Oncology*, vol. 30, no. 2, pp. 226–230, 2003.

[34] S. Y. Kristinsson, M. Björkholm, T. M.-L. Andersson et al., “Patterns of survival and causes of death following a diagnosis of monoclonal gammapathy of undetermined significance: a population-based study,” *Haematologica*, vol. 94, no. 12, pp. 1714–1720, 2009.

[35] S. Y. Kristinsson, S. Eloranta, P. W. Dickman et al., “Patterns of survival in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005,” *American Journal of Hematology*, vol. 88, no. 1, pp. 60–65, 2013.

[36] M. V. Dhodapkar, A. Hoering, M. A. Gertz et al., “Long-term survival in Waldenström macroglobulinemia: 10-year follow-up of Southwest Oncology Group directed intergroup trial S9003,” *Blood*, vol. 113, no. 4, pp. 793–796, 2009.

[37] T. Facon, M. Brouillard, A. Duhamel et al., “Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases,” *Journal of Clinical Oncology*, vol. 11, no. 8, pp. 1553–1558, 1993.

[38] P. Morel, M. Moncoutid, D. Jacomy et al., “Prognostic factors in Waldenström macroglobulinemia: a report on 232 patients...
with the description of a new scoring system and its validation on 253 other patients,” *Blood*, vol. 96, no. 3, pp. 852–858, 2000.

[39] G. Merlini, L. Baldini, C. Broglia et al., “Prognostic factors in symptomatic Waldenstrom’s macroglobulinemia,” *Seminars in Oncology*, vol. 30, no. 2, pp. 211–215, 2003.

[40] R. Garcia-Sanz, S. Montoto, A. Torrequebrada et al., “Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases,” *British Journal of Haematology*, vol. 115, no. 3, pp. 575–582, 2001.

[41] P. Morel, A. Duhamel, P. Gobbi et al., “International prognostic scoring system for Waldenstrom macroglobulinemia,” *Blood*, vol. 113, no. 18, pp. 4163–4170, 2009.

[42] R. M. de Tute, A. C. Rawstron, and R. G. Owen, “Immunoglobulin M concentration in Waldenstrom macroglobulinemia: correlation with bone marrow B cells and plasma cells,” *Clinical Lymphoma Myeloma and Leukemia*, vol. 13, no. 2, pp. 211–213, 2013.

[43] E. Kastritis, K. Zervas, P. Repoussis et al., “Prognostication in young and old patients with Waldenström’s macroglobulinaemia: importance of the international prognostic scoring system and of serum lactate dehydrogenase,” *Clinical Lymphoma and Myeloma*, vol. 9, no. 1, pp. 50–52, 2009.

[44] E. Kastritis, M. Kyrtsonis, E. Hadjiharissi et al., “Validation of the International Prognostic Scoring System (IPSS) for Waldenström’s Macroglobulinoma (WM) and the importance of serum lactate dehydrogenase (LDH),” *Leukemia Research*, vol. 34, no. 10, pp. 1340–1343, 2010.

[45] X. Leleu, W. Xie, M. Bagshaw et al., “The role of serum immunoglobulin free light chain in response and progression in Waldenstrom macroglobulinemia,” *Clinical Cancer Research*, vol. 17, no. 9, pp. 3013–3018, 2011.

[46] I. M. Ghobrial, R. Fonseca, M. A. Gertz et al., “Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia,” *British Journal of Haematology*, vol. 133, no. 2, pp. 158–164, 2006.

[47] S. Treon, C. Patterson, E. Kimby, and M. Stone, “Advances in the biology and treatment of Waldenström’s macroglobulinaemia: a report from the 5th international workshop on Waldenström’s macroglobulinaemia, Stockholm, Sweden,” *Clinical Lymphoma and Myeloma*, vol. 9, no. 1, pp. 10–15, 2009.

[48] I. M. Ghobrial, “Are you sure this is Waldenstrom macroglobulinemia?,” *American Society of Hematology Education Program*, vol. 2012, pp. 586–594, 2012.

[49] R. G. Owen, R. A. Kyle, M. J. Stone et al., “Response assessment in Waldenstrom macroglobulinaemia: update from the Vth International Workshop,” *British Journal of Haematology*, vol. 160, no. 2, pp. 171–176, 2013.

[50] M. Gertz, “Waldenstrom macroglobulinemia: my way,” *Leukemia & Lymphoma*, vol. 54, no. 3, pp. 464–471, 2013.

[51] M. A. Gertz, C. B. Reeder, R. A. Kyle, and S. M. Ansell, “Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique,” *Bone Marrow Transplantation*, vol. 47, no. 9, pp. 1147–1153, 2012.

[52] L. Souchet-Compain, S. Nguyen, S. Choquet, and V. Leblond, “Primary therapy of Waldenstrom macroglobulinemia with nucleoside analogue-based therapy,” *Clinical Lymphoma Myeloma and Leukemia*, vol. 13, no. 2, pp. 227–230, 2013.

[53] I. M. Ghobrial, “Choice of therapy for patients with Waldenstrom macroglobulinemia,” *Journal of Clinical Oncology*, vol. 31, no. 3, pp. 291–293, 2013.

[54] M. A. Dimopoulos, C. Zervas, A. Zomas et al., “Extended rituximab therapy for previously untreated patients with Waldenström’s macroglobulinemia,” *Clinical Lymphoma*, vol. 3, no. 3, pp. 163–166, 2002.

[55] M. A. Gertz, M. Rue, E. Blood, L. S. Kaminer, D. H. Vesole, and P. R. Greipp, “Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98),” *Leukemia and Lymphoma*, vol. 45, no. 10, pp. 2047–2055, 2004.

[56] S. P. Treon, A. Emmanouilides, E. Kimby et al., “Extended rituximab therapy in Waldenström’s macroglobulinemia,” *Annals of Oncology*, vol. 16, no. 1, pp. 132–138, 2005.

[57] S. P. Treon, J. D. Soumerai, Z. R. Hunter et al., “Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab,” *Blood*, vol. 118, no. 2, pp. 276–281, 2011.

[58] S. P. Treon, J. D. Soumerai, A. R. Branagan et al., “Thalidomide and rituximab in Waldenstrom macroglobulinemia,” *Blood*, vol. 112, no. 12, pp. 4452–4457, 2008.

[59] S. P. Treon, J. D. Soumerai, A. R. Branagan et al., “Lenalidomide and rituximab in Waldenström’s macroglobulinemia,” *Clinical Cancer Research*, vol. 15, no. 1, pp. 355–360, 2009.

[60] I. M. Ghobrial, M. Gertz, B. LaPlant et al., “Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia,” *Journal of Clinical Oncology*, vol. 28, no. 8, pp. 1408–1414, 2010.

[61] I. M. Ghobrial, A. Roccaro, F. Hong et al., “Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenström’s macroglobulinemia,” *Clinical Cancer Research*, vol. 16, no. 3, pp. 1033–1041, 2010.

[62] R. Garca-Sanz and E. M. Ocio, “Novel treatment regimens for Waldenstrums macroglobulinemia,” *Expert Review of Hematology*, vol. 3, no. 3, pp. 339–350, 2010.

[63] S. P. Treon, C. Hanzis, C. Tripsas et al., “Bendamustine therapy in patients with relapsed or refractory Waldenström’s macroglobulinemia,” *Clinical Lymphoma, Myeloma and Leukemia*, vol. 11, no. 1, pp. 133–135, 2011.

[64] M. Hensel, J. Brust, C. Plöger et al., “Excellent long-term survival of 170 patients with Waldenström’s macroglobulinemia treated in private oncology practices and a university hospital,” *Annals of Hematology*, vol. 91, no. 12, pp. 1923–1928, 2012.

[65] M. J. Stone and S. A. Bogen, “Evidence-based focused review of management of hyperviscosity syndrome,” *Blood*, vol. 119, no. 10, pp. 2205–2208, 2012.

[66] M. J. Stone and S. A. Bogen, “Role of plasmapheresis in Waldenström’s macroglobulinemia,” *Clinical Lymphoma Myeloma and Leukemia*, vol. 13, no. 2, pp. 238–240, 2013.

[67] S. P. Treon, C. K. Tripsas, B. T. Ciccarelli et al., “Patients with Waldenstrom macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration,” *Clinical Lymphoma Myeloma and Leukemia*, vol. 13, no. 2, pp. 241–243, 2013.

[68] S. P. Treon, “How I treat Waldenström macroglobulinemia,” *Blood*, vol. 114, no. 12, pp. 2375–2385, 2009.

[69] A. D’Souza, S. Ansell, C. Reeder, and M. A. Gertz, “Waldenstrom macroglobulinemia: the key questions,” *British Journal of Haematology*, 2013.
[102] A. W. Ho, E. Hatjiharissi, B. T. Ciccarelli et al., "CD27–CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia," *Blood*, vol. 112, no. 12, pp. 4683–4689, 2008.

[103] N. C. Gutiérrez, E. M. Ocío, J. de las Rivas et al., "Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals," *Leukemia*, vol. 21, no. 3, pp. 541–549, 2007.

[104] L. DuVillard, M. Guiguet, R.-O. Casasnovas et al., "Diagnostic value of serum IL-6 level in monoclonal gammopathies," *British Journal of Haematology*, vol. 89, no. 2, pp. 243–249, 1995.

[105] E. C. R. Hatzimichael, L. Christou, M. Bai, G. Kolios, L. Kefala, and K. L. Bourantas, "Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenström's macroglobulinemia," *European Journal of Haematology*, vol. 66, no. 1, pp. 1–6, 2001.

[106] S. P. Treon, C. J. Patterson, N. C. Munshi, and K. C. Anderson, "Proceedings of the seventh international workshop on waldenstrom macroglobulinemia," *Clinical Lymphoma Myeloma and Leukemia*, vol. 13, no. 2, pp. 181–183, 2013.

[107] S. Y. Kristinsson, J. Koshiol, M. Björkholm et al., "Immune-related and inflammatory conditions and risk of lymphoplasmaacytic lymphoma or Waldenström macroglobulinemia," *Journal of the National Cancer Institute*, vol. 102, no. 8, pp. 557–567, 2010.

[108] L. R. Goldin, M. Björkholm, S. Y. Kristinsson, I. Turesson, and O. Landgren, "Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia," *Haematologica*, vol. 94, no. 5, pp. 647–653, 2009.

[109] X. Liang, N. Caporaso, M. L. McMaster et al., "Common genetic variants in candidate genes and risk of familial lymphoid malignancies," *British Journal of Haematology*, vol. 146, no. 4, pp. 418–423, 2009.

[110] H. M. Ögmundsdóttir, S. Sveinsdóttir, Á. Sigfússon, I. Skaf-tadóttir, J. G. Jónasson, and B. A. Aagnarsson, "Enhanced B cell survival in familial macroglobulinaemia is associated with increased expression of Bcl-2," *Clinical and Experimental Immunology*, vol. 117, no. 2, pp. 252–260, 1999.

[111] W. J. Chng, R. F. Schop, T. Price-Troska et al., "Gene-expression profiling of Waldenström macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma," *Blood*, vol. 108, no. 8, pp. 2755–2763, 2006.

[112] E. Paramithiotis and M. D. Cooper, "Memory B lymphocytes migrate to bone marrow in humans," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 94, no. 1, pp. 208–212, 1997.

[113] J. L. Preud’homme and M. Seligmann, "Immunoglobulins on the surface of lymphoid cells in Waldenström's macroglobulinaemia," *Journal of Clinical Investigation*, vol. 51, no. 3, pp. 701–705, 1972.

[114] B. R. Smith, N. J. Robert, and K. A. Ault, "In Waldenström's macroglobulinemia the quantity of detectable circulating monoclonal B lymphocytes correlates with clinical course," *Blood*, vol. 61, no. 5, pp. 911–914, 1983.

[115] Y. Levy, J.-P. Fermand, S. Navarro et al., "Interleukin 6 dependence of spontaneously in vitro differentiation of B cells from patients with IgM gammopathy," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 87, no. 9, pp. 3309–3313, 1990.

[116] M. L. McMaster and N. Caporaso, "Waldenström macroglobulinaemia and IgM monoclonal gammopathy of undetermined significance: emerging understanding of a potential precursor condition," *British Journal of Haematology*, vol. 139, no. 5, pp. 663–671, 2007.

[117] H. T. Lynch, P. Watson, S. Tarantolo et al., "Phenotypic heterogeneity in multiple myeloma families," *Journal of Clinical Oncology*, vol. 23, no. 4, pp. 685–693, 2005.

[118] O. Landgren, S. Y. Kristinsson, L. R. Goldin et al., "Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammapathy of undetermined significance in Sweden," *Blood*, vol. 114, no. 4, pp. 791–795, 2009.

[119] T. Henry and R. Fonseca, "Genomics and proteomics in multiple myeloma and Waldenström macroglobulinemia," *Current Opinion in Hematology*, vol. 14, no. 4, pp. 369–374, 2007.

[120] E. M. Ocío, R. F. J. Schop, B. Gonzalez et al., "6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis," *British Journal of Haematology*, vol. 136, no. 1, pp. 80–86, 2007.

[121] E. Braggio, J. J. Keats, X. Leleu et al., "Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-κB signaling pathways in Waldenström's macroglobulinemia," *Cancer Research*, vol. 69, no. 8, pp. 3579–3588, 2009.

[122] L. Pascal, J. Gay, C. Willekens et al., "Bortezomib and Waldenström's macroglobulinemia," *Expert Opinion on Pharmacotherapy*, vol. 10, no. 5, pp. 909–916, 2009.

[123] A. M. Roccaro, A. Sacco, C. Chen et al., "MicroRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia," *Blood*, vol. 113, no. 18, pp. 4391–4402, 2009.

[124] E. Hatjiharissi, H. Ngo, A. A. Leontovich et al., "Proteomic analysis of Waldenstrom macroglobulinemia," *Cancer Research*, vol. 67, no. 8, pp. 3777–3784, 2007.

[125] M. J. Roberts, A. Chadburn, S. Ma, E. Hyjek, and L. C. Peterson, "Nuclear protein dysregulation in lymphoplasmaicytic lymphoma/waldenstrom macroglobulinemia," *American Journal of Clinical Pathology*, vol. 139, pp. 210–219, 2013.

[126] S. Zibelli, D. Capello, F. Forconi et al., "Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma," *Haematologica*, vol. 95, no. 10, pp. 1792–1796, 2010.

[127] A. Hadzidimitriou, A. Agathangelidis, N. Darzentas et al., "Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases," *Blood*, vol. 118, no. 11, pp. 3088–3095, 2011.

[128] A. Agathangelidis, N. Darzentas, A. Hadzidimitriou et al., "Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies," *Blood*, vol. 119, no. 19, pp. 4467–4475, 2012.

[129] E. Kostareli, M. Gounari, A. Janus et al., "Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity," *Leukemia*, vol. 26, no. 5, pp. 1127–1131, 2012.

[130] S. S. Sahota, F. Forconi, C. H. Ottensmeier et al., "Typical waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch event," *Blood*, vol. 100, no. 4, pp. 1505–1507, 2002.

[131] S. S. Sahota, F. Forconi, C. H. Ottensmeier, and F. K. Stevenson, "Origins of the malignant clone in typical Waldenström's macroglobulinemia," *Seminars in Oncology*, vol. 30, no. 2, pp. 136–141, 2003.

[132] J. Kriangkum, B. J. Taylor, S. P. Treon, M. J. Mant, A. R. Belch, and L. M. Pilarski, "Clonotypic IgM V/D/J sequence analysis..."
in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood," *Blood*, vol. 104, no. 7, pp. 2134–2142, 2004.

[133] J. Kriangkum, B. J. Taylor, S. P. Treon et al., "Molecular characterization of Waldenstrom’s macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences," *Clinical Cancer Research*, vol. 13, no. 7, pp. 2005–2013, 2007.

[134] J. Kriangkum, B. J. Taylor, E. Strachan et al., "Impaired class switch recombination (CSR) in Waldenstrom macroglobulinemia (WM) despite apparently normal CSR machinery," *Blood*, vol. 107, no. 7, pp. 2920–2927, 2006.

[135] G. Babbage, M. Townsend, N. Zojer et al., "IgM-expressing Waldenstrom’s macroglobulinemia tumor cells reveal a potential for isotype switch events in vivo," *Leukemia*, vol. 21, no. 4, pp. 827–830, 2007.

[136] P. Martin-Jiménez, R. García-Sanz, M. E. Sarasquete et al., "Functional class switch recombination may occur “in vivo” in Waldenstrom macroglobulinemia," *British Journal of Haematology*, vol. 136, no. 1, pp. 114–116, 2007.

[137] M. Varettioni, S. Zibellini, D. Capello et al., "Clues to the pathogenesis of Waldenstrom macroglobulinemia and IgM-MGUS provided by the analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors," *Leukemia & Lymphoma*, 2013.

[138] M. J. Stone, "Pathogenesis and morbidity of autoantibody syndromes in Waldenstrom’s macroglobulinemia," *Clinical Lymphoma, Myeloma and Leukemia*, vol. 11, no. 1, pp. 157–159, 2011.

[139] M. J. Stone and J. E. Fedak, "Studies on monoclonal antibodies. II. Immune complex (IgM IgG) cryoglobulinemia: the mechanism of cryoprecipitation," *Journal of Immunology*, vol. 113, no. 4, pp. 1377–1385, 1974.

[140] M. J. Stone, Y. G. McElroy, A. Peskon, J. L. Reynolds, J. T. Newman, and A. W. Tong, "Human monoclonal macroglobulins with antibody activity," *Seminars in Oncology*, vol. 30, no. 2, pp. 318–324, 2003.

[141] E. Nobile-Orazio, "Antigenic determinants in IgM paraprotein-related neuropathies," *Clinical Lymphoma and Myeloma*, vol. 9, no. 1, pp. 107–109, 2009.

[142] M. Kohler, H. Daus, and C. Kohler, "Lymphocytic plasmocytoid lymphoma with a three-banded gammapathy: reactivity of one of these paraproteins with cytomegalovirus," *Blut*, vol. 54, no. 1, pp. 25–32, 1987.

[143] J. Waldenstroem, S. Winblad, J. Haellen, and S. Liungman, "The occurrence of serological, “Antibody” reagins or similar gamma-globulins in conditions with monoclonal hypergamaglobulinemia, such as myeloma, macroglobulinemia Bc, etc.," *Acta medica Scandinavica*, vol. 176, pp. 619–631, 1964.

[144] V. Petrušić, I. Živković, M. Stojanović et al., "Antigenic specificity and expression of a natural idiotype on human pentameric and hexameric IgM polymers," *Immunologic Research*, vol. 51, no. 1, pp. 97–107, 2011.

[145] K. Preuss, G. Held, B. Kubuschok et al., "Identification of antigenic targets of paraproteins by expression cloning does not support a causal role of chronic antigenic stimulation in the pathogenesis of multiple myeloma and MGUS," *International Journal of Cancer*, vol. 121, no. 2, pp. 459–461, 2007.

[146] S. Grass, K. Preuss, S. Thome et al., "Paraproteins of familial MGUS/multiple myeloma target family-typical antigens: hyperphosphorylation of autoantigens is a consistent finding in familial and sporadic MGUS/MM,“ *Blood*, vol. 118, no. 3, pp. 635–637, 2011.

[147] S. Grass, K. Preuss, M. Ahlgrimm et al., "Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study," *The Lancet Oncology*, vol. 10, no. 10, pp. 950–956, 2009.

[148] S. R. Sompuram, G. Bastas, K. Vani, and S. A. Bogen, "Accurate identification of paraprotein antigen targets by epitope reconstruction," *Blood*, vol. 111, no. 1, pp. 302–308, 2008.

[149] M. Hecker, P. Lorenz, F. Steinbeck et al., "Computational analysis of high-density peptide microarray data with application from systemic sclerosis to multiple sclerosis,” *Autoimmunity Reviews*, vol. 11, no. 3, pp. 180–190, 2012.

[150] C.-A. Reynaud, M. Descatoire, I. Dogan, F. Huetz, S. Weller, and J.-C. Weill, "IgM memory B cells: a mouse/human paradox,“ *Cellular and Molecular Life Sciences*, vol. 69, no. 10, pp. 1625–1634, 2012.

[151] K. L. Good-Jacobson and D. M. Tarlinton, "Multiple routes to B-cell memory,” *International Immunology*, vol. 24, no. 7, pp. 403–408, 2012.

[152] U. Klein, K. Rajewsky, and R. Küppers, "Human immunoglobulin (Ig)M+IgD+ peripheral B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells,” *Journal of Experimental Medicine*, vol. 188, no. 9, pp. 1679–1689, 1998.

[153] S. G. Tangye, Y. Liu, G. Aversa, J. H. Phillips, and J. E. De Vries, "Identification of functional human splenic memory B cells by expression of CD148 and CD27,” *Journal of Experimental Medicine*, vol. 188, no. 9, pp. 1691–1703, 1998.

[154] M. A. Berkowska, G. J. A. Driessen, V. Bikos et al., "Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways,” *Blood*, vol. 118, no. 8, pp. 2150–2158, 2011.

[155] J. Kriangkum, B. J. Taylor, T. Reiman, A. R. Belch, and L. M. Pilarski, "Origins of Waldenström’s macroglobulinemia: does it arise from an unusual B-cell precursor?” *Clinical Lymphoma*, vol. 5, no. 4, pp. 217–219, 2005.

[156] S. Crotty, P. Felgner, H. Davies, J. Glidewell, L. Villarreal, and R. Ahmed, "Cutting edge: long-term B cell memory in humans after Smallpox vaccination," *Journal of Immunology*, vol. 171, no. 10, pp. 4969–4973, 2003.

[157] M. Maman-Matsuda, A. Cosma, S. Weller et al., "The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells,” *Blood*, vol. 111, no. 9, pp. 4653–4659, 2008.

[158] I. J. Amanna, N. E. Carlson, and M. K. Slifka, "Duration of humoral immunity to common viral and vaccine antigens,” *New England Journal of Medicine*, vol. 357, no. 19, pp. 1903–1915, 2007.

[159] D. Zotos and D. M. Tarlinton, "Determining germinal centre B cell fate,” *Trends in Immunology*, vol. 33, no. 6, pp. 281–288, 2012.

[160] V. Peperzak, I. B. Vikstrom, and D. M. Tarlinton, "Through a glass less darkly: apoptosis and the germinal center response," *Immunologic Research*, vol. 176, no. 9, pp. 1634–1636, 2013.

[161] S. Grass, K. Preuss, M. Ahlgrimm et al., "Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study,” *The Lancet Oncology*, vol. 10, no. 10, pp. 950–956, 2009.
I. Dogan, B. Bertocci, V. Vilmont et al., “Multiple layers of B cell memory with different effector functions,” Nature Immunology, vol. 10, no. 12, pp. 1292–1299, 2009.

K. A. Pape, J. J. Taylor, R. W. Maul, P. J. Gearhart, and M. K. Jenkins, “Different B cell populations mediate early and late memory during an endogenous immune response,” Science, vol. 331, no. 6021, pp. 1203–1207, 2011.

M. C. van Zelm, T. Szczepański, M. Van Der Burg, and J. J. M. Van Dongen, “Replication history of B lymphocytes reveals homeostatic proliferation and extensive antigen-induced B cell expansion,” Journal of Experimental Medicine, vol. 204, no. 3, pp. 645–655, 2007.

S. Weller, M. C. Braun, B. K. Tan et al., “Human blood IgM memory B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire,” Blood, vol. 104, no. 12, pp. 3647–3654, 2004.

C. Wei, J. Anolik, A. Cappione et al., “A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus,” Journal of Immunology, vol. 178, no. 10, pp. 6624–6633, 2007.

Y. Miura, R. Shimazu, K. Miyake et al., “RPI05 is associated with MD-1 and transmits an activation signal in human B cells,” Blood, vol. 92, no. 8, pp. 2815–2822, 1998.

P. Schneider, F. Mackay, V. Steiner et al., “BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth,” Journal of Experimental Medicine, vol. 189, no. 11, pp. 1747–1756, 1999.

H. Shu, W. Hu, and H. Johnson, “TALL-1 is a novel member of the TNF family that is down-regulated by mitogens,” Journal of Leukocyte Biology, vol. 65, no. 5, pp. 680–683, 1999.

J. Moreaux, E. Legouffe, E. Jourdan et al., “BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and drexamethasone,” Blood, vol. 103, no. 8, pp. 3148–3157, 2004.

Y. Wu, D. Kipling, H. S. Leong, V. Martin, A. A. Ademokun, and D. K. Dunn-Walters, “High-throughput immunoglobulin repertoire analysis distinguishes between human IgM memory and switched memory B-cell populations,” Blood, vol. 116, no. 7, pp. 1070–1078, 2010.

S. Weller, A. Faili, C. Garcia et al., “CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 3, pp. 1166–1170, 2001.

C. S. Ma, S. Pittaluga, D. T. Avery et al., “Selective generation of functional somatically mutated IgM CD27+ but not IgM isotype-switched, memory B cells in X-linked lymphoproliferative disease,” Journal of Clinical Investigation, vol. 116, no. 2, pp. 322–333, 2006.

K. Warnatz, L. Bossaller, U. Salzer et al., “Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency,” Blood, vol. 107, no. 8, pp. 3045–3052, 2006.

S. Weller, M. Bonnet, H. Delagreverie et al., “IgM+IgD+CD27+ B cells are markedly reduced in IRAK-4-, MyD88-, and TIRAP- but not UNC-93B-deficient patients,” Blood, vol. 120, no. 25, pp. 4992–5001, 2012.

S. Lin, Y. Lo, and H. Wu, “Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling,” Nature, vol. 465, no. 7300, pp. 885–890, 2010.

T. Kawagoe, S. Sato, K. Matsushita et al., “Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2,” Nature Immunology, vol. 9, no. 6, pp. 684–691, 2008.

C. Keim, D. Kazadi, G. Rothschild, and U. Basu, “Regulation of AID, the B-cell genome mutator,” Genes & Development, vol. 27, pp. 1–17, 2013.

S. Weller, M. Mamani-Matsuda, C.Picard et al., “Somatic diversification in the absence of antigen-driven responses is the hallmark of the IgM IgD CD27+ B cell repertoire in infants,” Journal of Experimental Medicine, vol. 205, no. 6, pp. 1331–1342, 2008.

F. A. Scheeren, M. Nagasawa, K. Weijer et al., “T cell-independent development and induction of somatic hypermutation in human IgM+IgD+CD27+ B cells,” Journal of Experimental Medicine, vol. 205, no. 9, pp. 2033–2042, 2008.

A. Tierens, J. Delabie, L. Michiels, P. Vandenberge, and C. De Wolf-Peeters, “Marginal-zone B cells in the human lymph node and spleen show somatic hypermutations and display clonal expansion,” Blood, vol. 93, no. 1, pp. 226–234, 1999.

I. Puga, M.Cols, C. Barra et al., “B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen,” Nature Immunology, vol. 13, no. 2, pp. 170–180, 2012.

F. Capolunghi, S. Cascio, E. Giorda et al., “CpG drives human transitional B cells to terminal differentiation and production of natural antibodies,” Journal of Immunology, vol. 180, no. 2, pp. 800–808, 2008.

A. Aranburu, S. Ceccarelli, E. Giorda, R. Lasorella, G. Ballatore, and R. Carsetti, “TLR ligation triggers somatic hypermutation in transitional B cells inducing the generation of IgM memory B cells,” Journal of Immunology, vol. 185, no. 12, pp. 7293–7301, 2010.

R. Ettinger, G. P. Sims, R. Robbins et al., “IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells,” Journal of Immunology, vol. 178, no. 5, pp. 2872–2882, 2007.

J. L. Karnell and R. Ettinger, “The interplay of IL-21 and BAFF in the formation and maintenance of human B cell memory,” Frontiers in Immunology, vol. 3, no. 2, 2012.

D. O. Griffin, N. E. Holodick, and T. L. Rothstein, “Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+CD27+CD43+CD70+,” Journal of Experimental Medicine, vol. 208, no. 1, pp. 67–80, 2011.

D. O. Griffin and T. L. Rothstein, “Human bl cell frequency: isolation and analysis of human bl cells,” Frontiers in Immunology, vol. 3, no. 122, 2012.

X. Zhong, W. Gao, N. Degaque et al., “Reciprocal generation of Th1/Th17 and T(reg) cells by B1 and B2 B cells,” European Journal of Immunology, vol. 37, no. 9, pp. 2489–2500, 2007.

A. B. Kantor, C. E. Merrill, L. A. Herzenberg, and J. L. Hillson, “An Unbiased Analysis of VH-D-JH Sequences from B-1a, B-1b, and Conventional B Cells,” Journal of Experimental Medicine, vol. 198, no. 3, pp. 1175–1186, 1997.

N. Baumgarth, “The double life of a B-1 cell: self-reactivity selects for protective effector functions,” Nature Reviews Immunology, vol. 11, no. 1, pp. 34–46, 2011.

M. Descatoire, J. Weill, C. Reynaud, and S. Weller, “A human equivalent of mouse B-1 cells?” Journal of Experimental Medicine, vol. 208, no. 13, pp. 2563–2564, 2011.

P. Martin, G. Christina, C. Teodosio, J. J. M. van Dongen, A. Orfao, and M. C. van Zelm, “The nature of circulating
CD27+CD43+ B cells,” *Journal of Experimental Medicine*, vol. 208, no. 13, pp. 2565–2566, 2011.

[195] S. G. Tangye and K. L. Good, “Human IgM’CD27’ B cells: memory B cells or “memory” B cells?” *Journal of Immunology*, vol. 179, no. 1, pp. 13–19, 2007.

[196] M. Seifert and R. Küppers, “Molecular footprints of a germinal center derivation of human IgM’ (IgD’)CD27 + B cells and the dynamics of memory B cell generation,” *Journal of Experimental Medicine*, vol. 206, no. 12, pp. 2659–2669, 2009.

[197] J. Weill, S. Weller, and C. Reynaud, “Human marginal zone B cells,” *Annual Review of Immunology*, vol. 27, pp. 267–285, 2009.

[198] L. Xu, Z. R. Hunter, G. Yang et al., “Circulating CD22low B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 32, pp. 13451–13456, 2009.

[199] K. Warnatz, A. Denz, R. Dräger et al., “Severe deficiency of switched memory B cells (CD27+IgM−IgD−) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease,” *Blood*, vol. 99, no. 5, pp. 1544–1551, 2002.

[200] B. Keller, S. Gutenberger et al., “Circulating CD22low B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 32, pp. 13451–13456, 2009.

[201] P. Tassone, P. Neri, J. L. Kutok et al., “ASCID-hu in vivo model of human Waldenström macroglobulinemia,” *Blood*, vol. 106, no. 4, pp. 1341–1345, 2005.
disease and with B symptoms,” Cancer Research, vol. 53, no. 9, pp. 2118–2122, 1993.

[226] L. T. Lam, G. Wright, R. E. Davis et al., “Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-kB pathways in subtypes of diffuse large B-cell lymphoma,” Blood, vol. 111, no. 7, pp. 3701–3713, 2008.

[227] N. Nishimoto, Y. Kanakura, K. Aozasa et al., “Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease,” Blood, vol. 106, no. 8, pp. 2627–2632, 2005.

[228] B. Klein, K. Tarte, M. Jourdan et al., “Survival and proliferation factors of normal and malignant plasma cells,” International Journal of Hematology, vol. 78, no. 2, pp. 106–113, 2003.

[229] M. Potter and C. L. Robertson, “Development of plasma-cell neoplasms in BALB/c mice after,” Journal of the National Cancer Institute, vol. 25, pp. 847–861, 1960.

[230] E. Shacter, G. K. Arradon, and J. Williams, “Elevation of interleukin-6 in response to a chronic inflammatory stimulus in mice: inhibition by indomethacin,” Blood, vol. 80, no. 1, pp. 194–202, 1992.

[231] A. Vink, P. Coulie, G. Warnier et al., “Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor,” Journal of Experimental Medicine, vol. 172, no. 3, pp. 997–1000, 1990.

[232] G. Lattanzio, C. Libert, M. Aquilina et al., “Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice,” American Journal of Pathology, vol. 151, no. 3, pp. 689–696, 1997.

[233] D. M. Hilbert, M. Kopf, B. A. Mock, G. Köhler, and S. Rudikoff, “Interleukin 6 is essential for in vivo development of B lineage neoplasms,” Journal of Experimental Medicine, vol. 182, no. 1, pp. 243–248, 1995.

[234] A. L. Kovalchuk, J. S. Kim, S. S. Park et al., “IL-6 transgenic mouse model for extragastrointestinal plasmacytoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 3, pp. 1509–1514, 2002.

[235] A. M. Ranger, B. A. Malynn, and S. J. Korsmeyer, “Mouse models of cell death,” Nature Genetics, vol. 28, no. 2, pp. 113–118, 2001.

[236] R. P. Bissonnette, F. Echeverri, A. Mahboubi, and D. R. Green, “Apoptotic cell death induced by c-myc is inhibited by bcl-2,” Nature, vol. 359, no. 6395, pp. 552–554, 1992.

[237] G. I. Evan, A. H. Wyllie, C. S. Gilbert et al., “Induction of apoptosis in fibroblasts by c-myc protein,” Cell, vol. 69, no. 1, pp. 119–128, 1992.

[238] D. L. Vaux, S. Cory, and J. M. Adams, “Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells,” Nature, vol. 335, no. 6189, pp. 440–442, 1988.

[239] A. Strasser, A. W. Harris, M. L. Bath, and S. Cory, “Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2,” Nature, vol. 348, no. 6299, pp. 331–333, 1990.

[240] C. M. Eischen, D. Woo, M. F. Roussel, and J. L. Cleveland, “Apoptosis triggered by Myc-induced suppression of Bcl-XL or Bcl-2 is bypassed during lymphomagenesis,” Molecular and Cellular Biology, vol. 21, no. 15, pp. 5063–5070, 2001.

[241] T. J. McDonnell, N. Deane, F. M. Platt et al., “bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation,” Cell, vol. 57, no. 1, pp. 79–88, 1989.

[242] A. Strasser, A. W. Harris, D. L. Vaux et al., “Abnormalities of the immune system induced by dysregulated bcl-2 expression in transgenic mice,” Current Topics in Microbiology and Immunology, vol. 166, pp. 175–181, 1990.

[243] T. J. McDonnell and S. J. Korsmeyer, “Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic in mice transgenic for the t(14;18),” Nature, vol. 349, no. 6306, pp. 254–257, 1991.

[244] A. Strasser, A. W. Harris, and S. Cory, “Equi-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells,” Oncogene, vol. 8, no. 1, pp. 1–9, 1993.

[245] C. Brunner, D. Marinkovic, J. Klein, T. Samardzic, L. Nitschke, and T. Wirth, “B cell-specific transgenic expression of Bcl2 rescues early B lymphopoiesis but not B cell responses in BOB.1/OBF.1-deficient mice,” Journal of Experimental Medicine, vol. 197, no. 9, pp. 1205–1211, 2003.

[246] J. J. Kenny, L. J. Rezanka, A. Lustig et al., “Autoreactive B cells escape clonal deletion by expressing multiple antigen receptors,” Journal of Immunology, vol. 164, no. 8, pp. 4111–4119, 2000.

[247] D. Corcos, A. Grandien, A. Vazquez, O. Dunda, P. Lorés, and D. Bucchini, “Expression of a V region-less B cell receptor confers a tolerance-like phenotype on transgenic B cells,” Journal of Immunology, vol. 166, no. 5, pp. 3083–3089, 2001.

[248] N. R. Ruetsch, G. C. Bosma, and M. J. Bosma, “Unexpected rearrangement and expression of the immunoglobulin lambda locus in scid mice,” Journal of Experimental Medicine, vol. 191, no. 1, pp. 1933–1943, 2000.

[249] M. Muramatsu, K. Kinoshita, S. Fagaras, S. Yamada, Y. Shinkai, and T. Honjo, “Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme,” Cell, vol. 102, no. 5, pp. 553–563, 2000.

[250] P. Revy, T. Muto, L. Levy et al., “Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2),” Cell, vol. 102, no. 5, pp. 565–575, 2000.

[251] J. Di Noia and M. S. Neuberger, “Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase,” Nature, vol. 419, no. 6902, pp. 43–48, 2002.

[252] A. R. Ramiro, M. Jankovic, T. Eisenreich et al., “AID is required for c-myc/IgH chromosome translocations in vivo,” Cell, vol. 118, no. 4, pp. 431–438, 2004.

[253] A. L. Kovalchuk, W. DuBois, E. Mushinski et al., “AID-deficient Bcl-xL transgenic mice develop delayed atypical plasma cell tumors with unusual Ig/Myc chromosomal rearrangements,” Journal of Experimental Medicine, vol. 204, no. 12, pp. 2989–3001, 2007.

[254] M. Takizawa, H. T. Á, Z. Li et al., “AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development,” Journal of Experimental Medicine, vol. 205, no. 9, pp. 1949–1957, 2008.

[255] W. F. Davidson, T. Giese, and T. N. Fredrickson, “Spontaneous development of plasmacytoid tumors in mice with defective fas fas ligand interactions,” Journal of Experimental Medicine, vol. 187, no. 11, pp. 1825–1838, 1998.

[256] J. Q. Zhang, C. Okumura, T. McCarty et al., “Evidence for selective transformation of autoreactive immature plasma cells in mice deficient in FasL,” Journal of Experimental Medicine, vol. 200, no. 11, pp. 1467–1478, 2004.

[257] J. W. Hartley, S. K. Chattopadhyay, M. R. Lander et al., “Accelerated appearance of multiple B cell lymphoma types in...”
NFS/N mice congenic for ecotropic murine leukemia viruses,”
Laboratory Investigation, vol. 80, no. 2, pp. 159–169, 2000.

[258] C. Qi, D. Shin, Z. Li et al., “Anaplastic plasmacytomas: relationships to normal memory B cells and plasma cell neoplasms of immunodeficient and autoimmune mice,” Journal of Pathology, vol. 221, no. 1, pp. 106–116, 2010.

[259] M. Gostissa, J. M. Bianco, M. D. Bianco et al., “Conditional inactivation of p53 in mature B cells promotes generation of nongerminall center-derived B-cell lymphomas,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 8, pp. 2934–2939, 2013.

[260] K. M. Nickerson, S. R. Christensen, J. Shupe et al., “TLR9 regulates TLR7- And MyD88-dependent autoantibody production and disease in a murine model of lupus,” Journal of Immunology, vol. 184, no. 4, pp. 1840–1848, 2010.

[261] L. L. Teichmann, D. Schenten, R. Medzhitov, M. Kashgarian, and M. J. Shlomchik, “Signals via the adaptor MyD88 in B cells and DCs make distinct and synergistic contributions to immune activation and tissue damage in lupus,” Immunity, vol. 38, no. 3, pp. 528–540, 2013.

[262] S. Silva, A. L. Kovalchuk, J. S. Kim, G. Klein, and S. Janz, “BCL2 Accelerates Inflammation-induced BALB/c Plasmacytomas and Promotes Novel Tumors with Coexisting T(12;15) and T(6;15) Translocations,” Cancer Research, vol. 63, no. 24, pp. 8656–8663, 2003.